<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN">
<html>
<head>
<meta name="Generator" content="SAS Software Version 9.4, see www.sas.com">
<meta http-equiv="Content-type" content="text/html; charset=utf-8">
<title>SAS Output</title>
<style type="text/css">
<!--
.accessiblecaption
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.aftercaption
{
  background-color: #FFFFFF;
  border-spacing: 0px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.batch
{
  background-color: #FFFFFF;
  border: 1px solid #000000;
  border-collapse: separate;
  border-spacing: 1px;
  color: #003399;
  font-family: 'SAS Monospace', 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  padding: 7px;
}
.beforecaption
{
  background-color: #FFFFFF;
  border-spacing: 0px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.body
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  margin-left: 8px;
  margin-right: 8px;
}
.bodydate
{
  background-color: #FFFFFF;
  border-spacing: 0px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  text-align: right;
  vertical-align: top;
  width: 100%;
}
.bycontentfolder
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: none;
  margin-left: 6pt;
}
.byline
{
  background-color: #FFFFFF;
  border-spacing: 0px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.bylinecontainer
{
  background-color: #FFFFFF;
  border: 0px solid #000000;
  border-spacing: 1px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  width: 100%;
}
.caption
{
  background-color: #FFFFFF;
  border-spacing: 0px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.cell
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.container
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.contentfolder
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: none;
  margin-left: 6pt;
}
.contentitem
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: none;
  margin-left: 6pt;
}
.contentproclabel
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: decimal;
}
.contentprocname
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: decimal;
}
.contents
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: decimal;
  margin-left: 8px;
  margin-right: 8px;
}
.contentsdate
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  width: 100%;
}
.contenttitle
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.continued
{
  background-color: #FFFFFF;
  border-spacing: 0px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
  width: 100%;
}
.data
{
  background-color: #FFFFFF;
  color: #000000;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.dataemphasis
{
  background-color: #FFFFFF;
  color: #000000;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.dataemphasisfixed
{
  background-color: #FFFFFF;
  color: #000000;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.dataempty
{
  background-color: #FFFFFF;
  color: #000000;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.datafixed
{
  background-color: #FFFFFF;
  color: #000000;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.datastrong
{
  background-color: #FFFFFF;
  color: #000000;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.datastrongfixed
{
  background-color: #FFFFFF;
  color: #000000;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.date
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  width: 100%;
}
.document
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.errorbanner
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.errorcontent
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.errorcontentfixed
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.extendedpage
{
  background-color: #FFFFFF;
  border: 1pt solid #000000;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
  text-align: center;
}
.fatalbanner
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.fatalcontent
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.fatalcontentfixed
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.folderaction
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.footer
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.footeremphasis
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.footeremphasisfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.footerempty
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.footerfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.footerstrong
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.footerstrongfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.frame
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.graph
{
  background-color: #FFFFFF;
  border: 1px solid #000000;
  border-collapse: separate;
  border-spacing: 0px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.header
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.headeremphasis
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.headeremphasisfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.headerempty
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.headerfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.headersandfooters
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.headerstrong
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.headerstrongfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.index
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.indexaction
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.indexitem
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: none;
  margin-left: 6pt;
}
.indexprocname
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: decimal;
}
.indextitle
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.linecontent
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list10
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list2
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list3
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list4
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list5
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list6
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list7
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list8
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list9
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem10
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem2
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem3
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem4
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem5
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem6
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem7
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem8
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem9
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.note
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.notebanner
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.notecontent
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.notecontentfixed
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.output
{
  background-color: #CCCCCC;
  border: 1px solid #000000;
  border-collapse: separate;
  border-spacing: 1px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.pageno
{
  background-color: #FFFFFF;
  border-spacing: 0px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
  text-align: right;
  vertical-align: top;
}
.pages
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: decimal;
  margin-left: 8px;
  margin-right: 8px;
}
.pagesdate
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  width: 100%;
}
.pagesitem
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: none;
  margin-left: 6pt;
}
.pagesproclabel
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: decimal;
}
.pagesprocname
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: decimal;
}
.pagestitle
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.paragraph
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.parskip
{
  background-color: #FFFFFF;
  border-spacing: 0px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.prepage
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.proctitle
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.proctitlefixed
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.rowfooter
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.rowfooteremphasis
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.rowfooteremphasisfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.rowfooterempty
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.rowfooterfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.rowfooterstrong
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.rowfooterstrongfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.rowheader
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.rowheaderemphasis
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.rowheaderemphasisfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.rowheaderempty
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.rowheaderfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.rowheaderstrong
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.rowheaderstrongfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.systemfooter
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemfooter10
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemfooter2
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemfooter3
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemfooter4
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemfooter5
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemfooter6
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemfooter7
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemfooter8
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemfooter9
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemtitle
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systemtitle10
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systemtitle2
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systemtitle3
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systemtitle4
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systemtitle5
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systemtitle6
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systemtitle7
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systemtitle8
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systemtitle9
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systitleandfootercontainer
{
  background-color: #FFFFFF;
  border: 0px solid #000000;
  border-spacing: 1px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  width: 100%;
}
.table
{
  background-color: #CCCCCC;
  border: 1px solid #000000;
  border-collapse: separate;
  border-spacing: 1px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.top_stacked_value
{
  padding-bottom: 1px;
  border: 0;
}
.middle_stacked_value
{
  padding-top: 1px;
  padding-bottom: 1px;
  border: 0;
}
.bottom_stacked_value
{
  padding-top: 1px;
  border: 0;
}
.titleandnotecontainer
{
  background-color: #FFFFFF;
  border: 0px solid #000000;
  border-spacing: 1px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  width: 100%;
}
.titlesandfooters
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.usertext
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.warnbanner
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.warncontent
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.warncontentfixed
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.l {text-align: left }
.c {text-align: center }
.r {text-align: right }
.d {text-align: right }
.j {text-align: justify }
.t {vertical-align: top }
.m {vertical-align: middle }
.b {vertical-align: bottom }
TD, TH {vertical-align: top }
.stacked_cell{padding: 0 }
-->
</style>
<script language="javascript" type="text/javascript">
<!-- 
function startup(){

}
function shutdown(){

}

//-->
</script>

</head>
<body onload="startup()" onunload="shutdown()" class="body">

<script language="javascript" type="text/javascript">
<!-- 
var _info = navigator.userAgent
var _ie = (_info.indexOf("MSIE") > 0
          && _info.indexOf("Win") > 0
          && _info.indexOf("Windows 3.1") < 0);
var _ie64 = _info.indexOf("x64") > 0

//-->
</script>

<div class="branch">
<a name="IDX"></a>
<table class="systitleandfootercontainer" width="100%" cellspacing="1" cellpadding="1" rules="none" frame="void" border="0" summary="Page Layout">
<tr>
<td class="c systemtitle">Obesity + IR + T2D data set 2</td>
</tr>
</table><br>
<div>
<div align="center">
<table class="table" cellspacing="1" cellpadding="7" rules="none" frame="box" summary="Procedure Print: Data Set REF2.OBESITY_IR_T2D_SORTED_2">
<colgroup>
<col>
<col>
<col>
</colgroup>
<thead>
<tr>
<th class="r header" scope="col">sub_ref_no</th>
<th class="l header" scope="col">Title</th>
<th class="l header" scope="col">Research_Gaps</th>
</tr>
</thead>
<tbody>
<tr>
<td class="r data">1</td>
<td class="l data">Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: a population-based cohort study</td>
<td class="l data">(A) Electronic health records (EHC) =&gt; 1.5 million individuals =&gt; 97823 diagnosed with T2D during medium follow-up 6.5 years =&gt; new BMI thresholds =&gt; obesity =&gt; trigger action to reduce risk of developing =&gt; T2D =&gt; Black, SA, Chinese + Arabs =&gt; living in England. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) Our data =&gt; address ongoing debate =&gt; interpretation of recommended BMI cutoffs =&gt; identifying obesity =&gt; minority ethnic popns. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) Equivalent age / sex adjusted incidence of T2D =&gt; BMI =&gt; 30.0 kg/m2 White popns =&gt; lower cutoffs =&gt; SA (23.9 kg/m2), Black (28.1 Kg/m2), Chinese (26.9 kg/m2) + Arab (26.6 kg/m2) popns. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Obesity =&gt; defined =&gt; BMI of 30.0 kg/m2 or more =&gt; widely used measure + important risk factor =&gt; development of T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) Appropriateness of this BMI cutoff =&gt; non-White minority ethnic popns =&gt; contentious =&gt; subject to debate =&gt; important limitations in the evidence base. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) Previous studies =&gt; identify BMI cutoffs for obesity =&gt; multi-ethnic popns =&gt; relied on prevalence data =&gt; BMI + T2D status =&gt; ascertained at the same timepoint =&gt; lacked precision =&gt; small sample size =&gt; used surrogate markers + self-reported data + included relatively few ethnic groups. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) WHO + NICE =&gt; both recommended a BMI cutoff of 27.5 kg/m2 =&gt; define obesity =&gt; SA&#39;s + Chinese popns =&gt; trigger lifestyle interventions. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) NICE =&gt; lower BMI threshold =&gt; used to trigger action to prevent T2D =&gt; Black popns. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) Our study =&gt; compared with risk of developing T2D at a BMI of 30.0 kg/m2 in White popns =&gt; equivalent risk in SA&#39;s =&gt; BMI 23.9 kg/m2 =&gt; much lower cutoff than recommended ethnicity specific cutoff of 27.5 kg/m2. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Our findings =&gt; consistent with previous studies =&gt; suggesting =&gt; cutoffs recommended by WHO + NICE =&gt; should be reduced  =&gt; non-White popns. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) For example =&gt; SABRE (Southall and Brent Revisited) cohort study =&gt; Europeans (n=1356), South Asians (n=842) + African-Caribbeans (n=335) =&gt; NW London, UK =&gt; aged 40 - 69 years at baseline =&gt; FU =&gt; median of 19 years =&gt; age + sex-adjusted BMI cutoffs for obesity =&gt; 25.2 kg/m2 SA + 27.2 kg/m2 for African-Caribbeans. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) Incidences of T2D among SA&#39;s =&gt; equivalent to that of White popn at lower BMI values. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Black ethnic subgroups =&gt; incidences of T2D equivalent to that of White popn at lower values ONLY for Black Caribbean individuals + Black people of other ethnic origins (NOT Black Africans, Black British, other Black people). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Also found =&gt; BMI cutoffs for overweight =&gt; based on risk of T2D =&gt; lower for SA&#39;s, Chinese, Arab vs White popn (25.0 kg/m2) =&gt; recommended BMI cutoff for overweight to reduce risk of T2D =&gt; also lowered in these groups. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (O) Improving + optimising =&gt; access to weight management service + therapies =&gt; for ethnic minorities =&gt; facilitate popn based management of obesity. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) Access to weight management services in England =&gt; determined by BMI cutoffs =&gt; our study shows =&gt; inadequate for establishing the risk of T2D =&gt; non-White minority ethnic popns. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) Choice of BMI cutoff for obesity related to T2D risk =&gt; profound effect on patient care =&gt; referrals to weight managment services, opportunistic + proactive screening for T2D + raising awareness more generally. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) Currently =&gt; WHO + NICE - recommended BMI cutoffs for obesity =&gt; DO NOT provide adequate basis for taking action. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) NICE recommendation =&gt; preventing T2D among Asian (SA + Chinese) popns =&gt; uses lower BMI threshold =&gt; 27.5 kg/m2 =&gt; indicates risk of T2D =&gt; equivalent to BMI of 30.0 kg/m2 in White popns. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) NICE =&gt; lower BMI threshold of 27.5 kg/m2 for Asian popns =&gt; should be used to trigger action to prevent T2D in Black popns. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) Our data =&gt; various BMI cutoffs =&gt; identify obesity based of T2D risk =&gt; Black ethnic subgroups. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (V) Well established + effective lifestyle strategies =&gt; prevention + delay in onset =&gt; T2D for those at risk. XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (W) Optimised glycaemic control =&gt; facilitates prevention + redn in progression =&gt; longer-term complications of T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (X) Without effective prevention + early diagnosis of T2D =&gt; advantages cannot by fully realised. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Y) Risk of T2D for several minority ethnic groups =&gt; under-recognised due to existing BMI cutoff criteria =&gt; recommended by WHO + NICE. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Z) Under-recognition =&gt; hinder opportunities for increased prevention + ealry diagnosis of T2D =&gt; minority ethnic groups. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (A1) Crucial =&gt; revise the classification of obesity =&gt; minority ethnic popns =&gt; using appropriate BMI cutoffs. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B1) Provide compelling data to support revision of BMI cutoffs currently used =&gt; trigger prevention of T2D in England. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C1) Revision =&gt; ensures that there is appropriate clinical surveillance =&gt; minor ethnic popns commensurate with their greater risk of T2D =&gt; preventing future onset =&gt; facilitate early + effective treatment of T2D. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D1) Whether lower BMI cutoffs in non-White populations are due to differences in body composition, biochemical characteristics, lifestyle factors (eg, physical activity or diet), the genetic architecture of type 2 diabetes, or lifestyle–gene interactions remains unclear. (25–27) Future studies that examine the relative contributions of these mechanisms to the development of type 2 diabetes might help to explain our study findings. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (E1) Further research is required to examine whether the same ethnicity-specific BMI cutoffs for overweight and obesity can be applied to trigger action to prevent type 2 diabetes in other countries.</td>
</tr>
<tr>
<td class="r data">2</td>
<td class="l data">The role of miR-320 in glucose and lipid metabolism disorder-associated diseases</td>
<td class="l data">(A) Glucose + lipid metabolism disorder associated diseases =&gt; effective prevention + treatment strategies remain elusive. XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) Reviewed miR-320 =&gt; potential biomarker for metabolic diseases =&gt; obesity + T2D + complications =&gt; new diagnostic strategy for these diseases. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) Effects of miR-320 =&gt; glucose + lipid metabolim disorder associated diseases. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Clinical application =&gt; multiple studies suggested that aberrant expression of miRNAs =&gt; essential roles in various diseases =&gt; provided a new therapeutic strategy.</td>
</tr>
<tr>
<td class="r data">3</td>
<td class="l data">Micro-ribonucleic acid-23a-3p prevents the onset of type 2 diabetes mellitus by suppressing the activation of nucleotide-binding oligomerization-like receptor family pyrin domain containing 3 inflammatory</td>
<td class="l data">(A) T2D =&gt; growing worldwide healthcare burden =&gt; tightly associated =&gt; widespread prevalance of obesity. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) Consequences =&gt; disrupted insulin secretion (IS) + insulin resistance (IR) =&gt; OR imbalance of carbohydrate (CHO), protein + lipid metabolisms. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) Progress on understanding T2D over recent decades has been developing  =&gt; BUT it&#39;s  a complicated chronic condition =&gt; healthcare burden + patient self-care =&gt; monitoring aberrant glucose level fluctuations. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Studies =&gt; develop + improve =&gt; effective + safer treatments. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) miRNA&#39;s =&gt; short non-coding RNA&#39;s (17 - 24 nucleotides) =&gt; bind to 3&#39; UTR (untranslated region) =&gt; targeted messenger RNA&#39;s =&gt; modulate gene expression =&gt; translational suppression or degradation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) miRNA&#39;s =&gt; regulate metabolisms correlated with T2D =&gt; insulin pathway + glucose homeostasis =&gt; feasibility as therapeutic targets =&gt; obesity + metabolic disorders. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) Plasma of CV patients =&gt; observed to carry inhibited expression of miR-2319 =&gt; some research =&gt; miR-23 =&gt; plays a role in glucose metabolism =&gt; dog muscles. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) Current study =&gt; expression of miR-23a-3p + NEK7 =&gt; -vely correlated in patients + rat models =&gt; T2D. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) More specifically =&gt; miR-23a-3p =&gt; downregulated + NEK7 =&gt; upregulated. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Prediction functionality of TargetScan software =&gt; predicting presence of a targeted binding site =&gt; miR-23a-3p + NEK7 =&gt; 3&#39;UTR =&gt; proved miR-23a-3p -vely regulates NEK7 expression by binding to it&#39;s 3&#39;UTR region. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) -ve regulation of NEK7 =&gt; affects expression of NLRP3 inflammatory bodies =&gt; consistent with another finding =&gt; NEK7 =&gt; regulates activation of NLRP3 inflammatory bodies. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) Recent studies =&gt; novel forms of programmed cell death =&gt; necroptosis + pyroptosis. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Pyroptosis =&gt; pro-inflammatory form of programmed cell death =&gt; dependent on enzymatic function of inflammatory proteases =&gt; cysteine-dependent aspartate-specific caspase family. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Pyroptosis =&gt; mostly reported to occur in phagocytes of the myeloid lineage =&gt; neutrophils, macrophages + dendritic cells, epithelial cells, endothelial cells + neurons. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) Underlying potential mechn =&gt; above cells =&gt; higher expression levels of inflammatory capases =&gt; promote pyroptosis e.g. caspase-122. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) Inflammasomes are multimeric ( a protein composed of several subunits) protein structures =&gt; govern inflammatory reactions + pyroptosis =&gt; host&#39;s defenses to prevent microbial invasion. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) Sensors of inflammasomes =&gt; closely related to apoptosis-associated speck-like protein =&gt; contains apoptosis-associated speck-like protein =&gt; containing a C-terminal caspase recruitment domain =&gt; trigger inflammatory caspase-1 =&gt; secretion of inflammatory cytokines =&gt; programmed cell death =&gt; enable host defensive responses =&gt; fighting pathogens. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) Capability of NLRS =&gt; construct inflammasomes =&gt; attributed to =&gt; NLF-family pyrin domain-containing 1 (NLRP1). XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) Increased prodn of reactive oxygen species (ROS) + thiol oxidn =&gt; stimulate NEK7-dependent NLRP3 activation =&gt; decrease in NADH level + mitochondrial ROS level =&gt; dysregulation of cellular glycolytic flux =&gt; further promote NLRP3 inflammasomes + pyroptosis. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) We found that =&gt; miR-23a-3p =&gt; inhibits pyroptosis =&gt; through the inactivation of NEK7 / NLRP3 inflammatory bodies =&gt; verified by overexpressing miR-23a-3p, depleting miR-23a-3p or depleting NEK7 experiment. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) Provided evidence =&gt; miR-23a-3p =&gt; target NEK7 =&gt; further inhibit activation of NLRP3 =&gt; suppressed pyroptosis. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (V) Symptoms of T2D in rats =&gt; mitigated. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (W) These results gave us implications that the miR-23a-3p–NEK7–-NLRP3 axis could be utilized as a potential therapeutic target in the alleviation or treatment of type 2 diabetes mellitus in the future.</td>
</tr>
<tr>
<td class="r data">4</td>
<td class="l data">The Gut Microbiota in Prediabetes and Diabetes: A Population-Based Cross-Sectional Study</td>
<td class="l data">(A) Popn-based cross-sectional study =&gt; significant alterations of gut microbiota (at both compositional + functional potential levels) =&gt; diabetes-treatment-naïve T2D =&gt; discovery cohort =&gt; confirmed findings in validation cohort. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) Alterations of the gut microbiota are already present in individuals with prediabetes =&gt; BUT more pronounced in people with CGI + strongly linked to IR state. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) Our evidence =&gt; link between =&gt; gut microbiota + pre-diabetes + T2D =&gt; consistent with earlier studies. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) This finding =&gt; independent of metformin =&gt; major confounding factor =&gt; gut microbiota, ALSO independent of treatment with statins + PPI + other confounders =&gt; age, sex + BMI. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) Our analysis =&gt; differences between the IFG + IGT groups =&gt; more pronounced changes in microbiota of individuals =&gt; IGT despite comparable BMI in IFG + IGT groups. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) Earlier studies =&gt; higher risk =&gt; T2D + CVD =&gt; in those =&gt; IGT / CGI (combined glucose intolerance) vs IFG. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) IGT + IFG =&gt; earlier shown =&gt; associate with peripheral + hepatic IR respectively + modification =&gt; gut microbiota =&gt; by dietary fibre supplementation OR transplantation of fecal microbiota =&gt; from insulin sensitive individuals =&gt; improves =&gt; peripheral &gt; hepatic insulin sensitivity =&gt; individuals with metabolic syndrome. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) Do not have direct measurements =&gt; hepatic + peripheral IR =&gt; cannot exclude a potential role for the gut microbiota =&gt; hepatic insulin signalling. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) Link =&gt; gut microbiota composition + IR =&gt; further supported =&gt; our distance-based redundancy analysis + microbiome-based maching learning model =&gt; distinguish =&gt; (combined glucose intolerance) CGI / T2D or NGT. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Specifically =&gt; improved AUC (0.78) =&gt; applying the model =&gt; two subgroups =&gt; validation cohort =&gt; lowest + highest IR. XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) Consistent with our results =&gt; two recent longitudinal studies =&gt; strong connection =&gt; microbiome + IR =&gt; identified host-microbe interactions =&gt; differed between =&gt; insulin-sensitive + IR individuals. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) Circulating levels of microbial metabolite imidazole propionate =&gt; increased  =&gt; CGI / T2D =&gt; discovery cohort =&gt; microbial potential =&gt; biosynthesis =&gt; BCAA&#39;s =&gt; increased in the gut microbiota =&gt; CGI =&gt; both cohorts. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Imidazole propionate + BCAA&#39;s =&gt; affect insulin signalling =&gt; mTORC1 =&gt; potential causal links =&gt; microbiota + IR. XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Our results =&gt; functional potential =&gt; gut microbiota =&gt; potential interactions =&gt; gut microbiota + diet =&gt; important =&gt; onset of T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) Enrichment in bacterial pathways for biotin biosynthesis =&gt; gut microbiota of groups with IGT, CGI or T2D. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) Bacteria only produce biotin when environmental supply is insufficient, our data =&gt; IGT, CGI or T2D =&gt; deficient in biotin =&gt; deficiency =&gt; affects gut microbiota + function. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) Biotin deficiency in T2D =&gt; reported =&gt; several studies =&gt; supplementation with biotin =&gt; improves glucose metabolism =&gt; no conclusive evidence =&gt; future studies req&#39;d =&gt; accurately determine whether biotin deficiency =&gt; pathogenesis T2D. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) Observed =&gt; redn of metagenomic species that are butyrate producers =&gt; IGT, CGI + T2D vs low risk NGT + (discovery + validation cohorts) =&gt; respectively + IFG groups vs combined NGT group in discovery cohort. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) Increased intestinal prodn of butyrate =&gt; function of host genetics =&gt; recently linked to improved insulin response after OGTT. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) Abundance + function of butyrate producers =&gt; strongly modulated by diet + particularly fibre intake + benefits of glucose control. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) Supplementation of fermentable fibres =&gt; T2D =&gt; enhanced butyrate prodn in parallel =&gt; redn HbA1c. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (V) Loss of butyrate producers =&gt; observed repeatedly =&gt; fetal microbiota of people =&gt; prediabetes + T2D. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (W) Our results =&gt; extend earlier work =&gt; loss of butyrate producers + genes of butyrate synthesis =&gt; from CHD + proteins =&gt; occurs in prediabetes + greater extent =&gt; IGT + CGI. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (X) Potential causal role for butyrate producers +/- butyrate itself =&gt; etiology of glucose intolerance + progression to T2D. XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Y) Long-term perspective =&gt; replenishment of butyrate prodn in gut microbiota of people with prediabetes =&gt; targeted approach =&gt; prevent / delay =&gt; progression to T2D. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Z) Our study =&gt; minority of potential butyrate producers =&gt; higher abundance =&gt; IGT, CGI or T2D vs NGT. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (A1) Included =&gt; opportunistic pathogens =&gt; Clostridium clostridioforme cluster ( C.clostridioforme + C.boltene) =&gt; reported in gut microbiota of subjects with T2D =&gt; different ethnic backgrounds + obesity + markedly IR + dyslipidaemia. XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B1) Our analysis =&gt; genomes of potential butyrate producer =&gt; increased in abundance + contained genes related to virulence. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C1) Understanding reasons for consistent expansion of opportunistic pathogens =&gt; reveal =&gt; important intestinal pathophysiological targets =&gt; development of IGT + T2D. XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D1) CONCLUSIONS =&gt; robust covariation of the gut microbiota =&gt; IGT, CGI + T2D =&gt; independent of metformin. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E1) Alterations of gut microbiota associated with IR BUT not fasting glucose. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F1) Our findings =&gt; consistent =&gt; possibility =&gt; gut microbiota =&gt; modifiable determinant of T2D + closely related to dietary factors. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G1) Although biotin deficiency in T2D has been reported (Maebashi et al., 1993) and several studies indicate that supplementation with biotin may improve glucose metabolism (Albarracin et al., 2008; Fernandez-Mejia, 2005; Lazo de la Vega-Monroy et al., 2013), there is no conclusive evidence, and future studies are required to accurately determine whether biotin deficiency plays a role in the pathogenesis and development of T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H1) Future studies should test whether restoration of altered microbial functions, such as butyrate production, in individuals with IGT and CGI might constitute a precision medicine approach to prevent or delay the progression to T2D. XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">5</td>
<td class="l data">Metabolomic Markers of Kidney Function Decline in Patients With Diabetes: Evidence From the Chronic Renal Insufficiency Cohort (CRIC) Study</td>
<td class="l data">(A) 3-HIBA reduced in established DKD BUT increased in progressive DKD. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) 3-HIBA METABOLISM =&gt; XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX VALINE =&gt; 3-HIBA =&gt; Drive vascular fatty acid transport =&gt; uptake into cardiac endothelial cells XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) Elevated plasma levels BCAA + 3HIBA =&gt; associated with obesity + T2D. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) 3HIBA =&gt; associated with excess angiogenesis =&gt; contributing factor =&gt; progressive DKD. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (E) HIBA =&gt; involved in propanoate metabolism =&gt; +ve assocaition with IR + ketoacidosis. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (F) Tiglycine =&gt;  metabolites of BCAA degradation =&gt; the levels reduced in established DKD. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX   (G) For future work, we will use independent cohorts with varying clinical risk profiles to further evaluate our findings. A future aim is to evaluate our models on clinically distinct patient populations (e.g., by albuminuria group), and develop new signatures using an expanded set of metabolites.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) Second, non-targeted metabolomics by flow-injection analysis cannot distinguish between metabolites with identical sum formula and only reports relative abundance change. In future work, we will use targeted gas chromatography-mass spectrometry or liquid chromatography–tandem mass spectrometry methods to replicate these findings. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) Third, our “two-stage” approach to modeling kidney disease progression via eGFR slope has the advantage of being easy to interpret and analyze since standard statistical methods can be employed. However, this approach could entail an efficiency loss when there are missing data or irregular spaced repeated measures. A future aim is to develop appropriate weighting methods for unbalanced data. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Finally, eGFR decline may not always be linear. However, despite the linearity assumption, eGFR slope offers ease of biological interpretation, and permits application of standard statistical modeling methods. Importantly, the CRIC Study has produced notable findings with eGFR slope as a marker for kidney disease progression (39,40). Nevertheless, we aim to examine nonlinear trajectories in future work.</td>
</tr>
<tr>
<td class="r data">6</td>
<td class="l data">Lysine pathway metabolites and the risk of type 2 diabetes and cardiovascular disease in the PREDIMED study: results from two case-cohort studies</td>
<td class="l data">(A) Baseline lysine + 2AAA associated with future T2D but not with CVD risk. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX   (B) Baseline diabetic status modifies association of lysine levels and CVD risk. Diabetes at basline is associated with higher lysine levels and increased risk of CVD. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) 1 year changes in lysine, 2-AAA, pipecolic acid not associated with CVD risk. XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) MEDDIET =&gt; no significant effect on 1 year changes in 2-AAA or lysine. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (E) MEDDIET =&gt; + nuts or EVOO =&gt; reduced CVD / T2D risk =&gt; regulation of different biological mechanisms than those related to lysine degradation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) MEDDIET =&gt; may be modifiying the risk conferred by high levels of metabolites in the lysine degradation pathway. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) Framingham Heart Study (FHS) + Malmo Diet + Cancer Study (MDC) =&gt; 2-AAA predicted risk of T2D in normoglycaemic individuals. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) High CVD risk patients  =&gt; associated with high baseline levels 2-AAA =&gt; higher subsequent risk of T2D risk =&gt; in Mediterranean popn. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) Possible to predict risk of developing T2D from 2-AAA at prediabetic stage. XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (j) Similarly lysine can predict T2D at prediabetes stage but the association is less strong. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (k) Cross-sectional study 2-AAA associated with obesity + metabolic syndrome + T2D, lysine similar but weaker associations. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) Mechanisms =&gt; 2-AAA elevated in response to high glucose levels =&gt; increased insulin secretion =&gt; promoting mechanisms of maintaining glucose homeostasis in early IR. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX X (M) Lysine may be elevated at an early stage of this pathophysiological process to provide the 2-AAA substrate for a likely compensatory mechanism. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Lysine =&gt; predictor of IR + gestational diabetes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) Increased levels 2-AAA + pipecolic acid =&gt; diabetic corneas, suggesting this pathway may be also related to diabetes induced diseases. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) Non-diabetic patients =&gt; 2-AAA + pipecolic acid + lysine levels not associated with CVD. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (Q) Diabetic patients =&gt; lysine associated with CVD, diabetic status may behave as an effect modifier of the association between lysine + CVD =&gt; p-value statistically significant interaction =&gt; this finding is a novelty =&gt; future replication in further independent cohorts. This effect modification by pre-existent diabetes =&gt; lysine may be implicated in development of complications associated with diabetes =&gt; high lysine levels =&gt; biomarker  =&gt; poorer control of glycaemic levels in T2D. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) 2-AAA pathway of lysine degradation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Lysine =&gt; L-homoarginine =&gt; NO synthesis, related to CVD + T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (S) MEDDIET =&gt; no effect on lysine  + 2-AAA or pipecolic acid 1 year changes. + no multiplicative interaction =&gt; MEDDIET intervention + 1 year changes in lysine , 2-AAA + pipecolic acid. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX X (T) MEDDIET =&gt; modifying the effects of baseline lysine =&gt; CVD risk =&gt; there was no significant interaction between lysine and the intervention + 2-AAA + pipecolic acid =&gt; non-significant interaction of MEDDIET + EVOO lysine + intervention. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) No direct effect of diet on the levels of metabolites, but MEDDIET may be modifying effects of metabolites on CVD or T2D risk affecting other mechanisms =&gt; mechanisms =&gt; different metabolic pathways, inflammation or oxidn. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (V) Diabetes related association of lysine + CVD risk XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (W) Further studies are needed to clarify the effect of diet on lysine, 2-AAA and pipecolic acid levels and the potential effect modification by dietary interventions on the CVD/T2D risk associated with these metabolites. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (X) Thus, new studies are needed to evaluate if lysine pathway metabolites may add value to the prediction of risk provided by HbA1c. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Y) Consequently, these results, especially those suggesting a potential interaction between the nutritional intervention and these 2 metabolites deserve further confirmation in independent prospective cohort studies and trials [24]. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">7</td>
<td class="l data">Plasma Lipidomic Profiling and Risk of Type 2 Diabetes in the PREDIMED Trial</td>
<td class="l data">(A) Baseline LP (LPC + LPE), PC-PL, SM + CE scores =&gt; inversely assoc. with risk of T2D, BUT baseline TAG, DAG + PE scores directly assoc. with T2D. XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) 1 year changes in these scores =&gt; assoc. beyond baseline levels =&gt; mainly non-significant =&gt; BUT point estimates remained in the same direction, BUT 1-year changes had suboptimal power. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) LPC&#39;s + LPE&#39;s =&gt; grouped as LP&#39;s =&gt; reduced risk of T2D. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) LPC levels were lower in individual&#39;s with obesity, IR + T2D, increased levels of LPC&#39;s =&gt; indicators of metabolic health =&gt; obesity, LPC =&gt; glucose lowering + anti-inflammatory effects. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) LPC + LPE levels =&gt; lower in T2D + patients with T2D, with lower levels of these lipids =&gt; increased risk of CVD. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) Similarly to LP =&gt; PCPLs inversely related to T2D. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) Plasmalogens =&gt; roles as endogenous anti-oxidants limiting the oxidn of other lipids + reduced risk of T2D through other beneficial mechns =&gt; antiapoptotic + anti-inflammatory functions. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) EPIC-Potsdam study =&gt; inverse assoc. of SM&#39;s + T2D consistent with the results of current study. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) Patients with prediabetes / diabetes =&gt; inverse associations plasma odd-chain SM&#39;s + T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Knockout model of SM synthase =&gt; mitochondrial dysfunction + impaired glucose-stimulated insulin secretion =&gt; mechanistic support for our findings. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) Inverse association of CE&#39;s + T2D =&gt; previous cross-sectional studies =&gt; strong direct associations with T2D. Similar inverse assoc. CE&#39;s + CVD in the PREDIMED trial =&gt; possible =&gt; detected the defined &quot;atherogenic lipoprotein phenotype&quot; =&gt; patient at high risk of T2D (high plasma levels of TAG&#39;s, low levels of HDL + atypically dense LDL particles). XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) LDL particles are loaded with TAG&#39;s instead of CE&#39;s + after the hydrolysis of TAG&#39;s in the liver =&gt; lipid-depleted LDL particles (small + dense) =&gt; released. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) By losing their lipid core =&gt; the particles lose anti-oxidant vitamins =&gt; oxidatively damaged =&gt; trigger foam cell formation =&gt; atherosclerosis. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Lipoprotein phenotype =&gt; IR + eventually T2D. XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) DAG, TAG + PE scores =&gt; strongly assoc with higher risk T2D. High circ levels of DAG + short TAG&#39;s =&gt; assoc. with T2D. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) Our findings =&gt; confirm +ve assoc =&gt; highlighting adverse role of short + saturated + low unsaturated species. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) After adjusting for individual TAG for total TAG score =&gt; odd chain TAG&#39;s inversely assoc. with T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) Odd chain FA&#39;s =&gt; especially C15:0 + C17:0 =&gt; biomarkers of diary product intake =&gt; inversely assoc. with T2D + CVD. Important to consider specific FA content of TAG&#39;s =&gt; plasma risk profiles for T2D. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) Our results =&gt; confirm previous studies =&gt; PE&#39;s assoc. with high fasting glucose + T2D. PE&#39;s are a minor species in plasma =&gt; important structural lipids in membranes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) Increased PE&#39;s + imbalance between PC + PE =&gt; related to obesity + NAFLD =&gt; related to T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) Our results =&gt; important implications =&gt; clarify the biological mechns =&gt; link between dyslipidaemia + T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (V) Subjects of high T2D risk + plasma lipid profile =&gt; high levels of DAG&#39;s, short TAG&#39;s + PE&#39;s + low levels of LP&#39;s, PC-PL&#39;s, SM&#39;s + CE&#39;s =&gt; also identified before T2D onset =&gt; enable early intervention.</td>
</tr>
<tr>
<td class="r data">8</td>
<td class="l data">Fine-mapping of an expanded set of type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps</td>
<td class="l data">(A) Combined GWAS (genome-wide-association-study) =&gt; observational study =&gt; genome-wide set of genetic variants =&gt; different individuals =&gt; to see if any variant is associated with a trait. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) GWAS =&gt; typically focus on associations =&gt; single nucleotide polymorphisms (SNP&#39;s) + traits =&gt; major human disease BUT =&gt; equally be applied to any other genetic variant + any other organisms. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) Combined GWAS data =&gt; 32 studies =&gt; 74,124 T2D cases + 824,006 controls of European ancestry (effective sample size 321,436). XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) This represents 3.2-fold increase =&gt; effective sample size =&gt; previous largest GWAS of T2D risk in Europeans. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) This sample size =&gt; assuming accurate imputation (imputation quality score &gt; 0.8) =&gt; 80% power to detect T2D association (at a = 5 x 10 -8) with variants of minor allele frequency (MAF) &gt;=5% + odds ratio (OR) &gt;= 1.10 or MAF &gt;=0.1% + OR &gt;= 1.60. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) MAF definition =&gt; frequency at which the second most common allele that occurs in a given popn. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) MAF&#39;s play a surprising role in heritability =&gt; MAF variants occur only once =&gt; known as &#39;singletons&#39; =&gt; drive an enormous amount of selection. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) After stringent harmonised quality control =&gt; 31 of the 32 GWAS =&gt; imputed using the 64,976 whole-genome sequenced haplotypes. XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) A haplotype (haploid genotype) is a group of alleles in an organism that are inherited together from a single parent. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Many organisms =&gt; genetic material (DNA) =&gt; inherited from BOTH parents. X XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) Organisms =&gt; organise DNA =&gt; two sets of pairwise similar chromosomes. XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) Offspring =&gt; gets one chromosome in each pair from each parent. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Diploid =&gt; pairs of chromosomes; Haploid =&gt; one half of each pair. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) The haploid genotype (haplotype) =&gt; genotype =&gt; that considers the singular chromosomes vs pairs of chromosomes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) It can be all the chromosomes from one of the parents OR a minor part of a chromosome =&gt; e.g. sequences of 9000 base pairs of the Haplotype Reference Consortium (HRC) =&gt; exception =&gt; deCODEGWAS =&gt; imputed using popn-specific reference panel based on 30,440 Icelandic whole-genome sequenced haplotypes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) Conducted =&gt; T2D association analyses =&gt; with + without adjustment =&gt; BMI. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) DISCOVERY OF NOVEL LOCI FOR T2D SUSCEPTIBILITY =&gt; Tested for T2D association with 27 million genotyped or imputed variants passing quality control filters =&gt; 21 million with MAF &lt; 5%. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) GWAS meta-analysis identified =&gt; variants at 231 loci at genome-wide significance (p &lt; 5 x 10 -8 ) =&gt; BMI unadjusted analysis + 152 in the smaller (effective sample size 157,401) BMI-adjusted analysis. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) BMI adjusted signals =&gt; 140 overlapping with the BMI-unadjusted analysis + 12 genome-wide significant only after adjustment. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) Of these 243 loci (231 + 12) =&gt; 172 =&gt; significant at a more stringent threshold =&gt; (p &lt; 5 x 10 -9) =&gt; advocated for whole genome-wide significant. (overly conservative GWAS). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) Of the 243 significant loci =&gt; 135 mapped outside regions previously-implicated in T2D risk =&gt; defined =&gt; &gt; 500kb from reported lead variants. XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (V) The MAF of lead variants at 135 novel loci =&gt; 0.02% to 49.7% =&gt; including 9 low-frequency (0.5% =&lt; MAF &lt; 5%) + rare (MAF &lt; 0.5%) variant signals. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (W) Samples not included =&gt; previous discovery efforts (42,734 cases + 497,261 controls) =&gt; replicated associations (directionally consistent at p &lt; 0.05) at 126 of 141 previously reported  T2D loci =&gt; including =&gt; 1st discovered European-only or trans-ethnic efforts. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (X) Significant European Signals (p &lt;0.05) for 20 other loci =&gt; initially reported in studies =&gt; non-European subjects. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Y) 15 signals did not replicate =&gt; all 1st identified in non-European samples =&gt; 6 =&gt; reported lead variant had MAF &lt; 1% in Europeans. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Z) MULTIPLE ASSOCIATION SIGNALS AT T2D SUSCEPTIBILITY LOCI =&gt; We used approximate conditional analysis with GCTA12 =&gt; delineate distinct association signals =&gt; multiple causal variants =&gt; same locus. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (A1) Across 243 associated loci =&gt; 160 additional signals =&gt; &quot;locus-wide&quot; significance (previous T2D analysis =&gt; define =&gt; locus-specific threshold =&gt; p &lt; 10 -5), 110 previously reported T2D loci. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B1) Of these 160 signals =&gt; 92 met more conservative association =&gt; threshold p &lt; 10 -6. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C1) Observed 1 signal at 151 loci + 2 - 10 signals at the remaining 92, for a total of 403 significant T2D-association signals. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D1) Analyses =&gt; revealed marked complexity at some associated loci. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E1) 1st time =&gt; evidence of multiple association signals at the TCF7L2 locus =&gt; largest-effect common variant signal for T2D in Europeans. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F1) Seven additional distinct signals =&gt; (0.5 &lt; MAF &lt; 47.6%, OR 1.05 &lt; OR &lt; 1.36) =&gt; index variants =&gt; weak LD (r2 &lt; 0.06) with previously reported lead GWAS SNP, rs 7903146 (OR 1.37, MAF 29.3%). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G1) Most spectacularly =&gt; 1Mb region =&gt; previously annotated INS-IGF2 and KCNQ1 loci =&gt; compelling evidence  =&gt; conditional analysis =&gt; 5 + 10 independent (r2 &lt; 0.25) non-coding index variants, respectively (0.15% &lt; MAF &lt; 42.8%, 1.03 &lt; OR &lt; 1.68). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H1) Adjacent of these 2 loci =&gt; region notable for multiple imprinting  effects =&gt; include many strong biological candidates (including INS, IGF2, KCNQ1 + CDKN1C) =&gt; previously-unheralded degree of complexity-T2D-associated telomeric region of Chromosome 11. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I1) Telomere =&gt; (greek =&gt; telos &#39;end&#39; + meros &#39;part&#39;) =&gt; region of repetitive nucleotide sequences =&gt; associated specialised protein at the ends of linear chromosomes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J1) Telomeres =&gt; widespread genetic feature =&gt; commonly found in eukaryotes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K1) Most if not all species possessing them =&gt; protect the terminal regions of chromosomal DNA =&gt; progressive degradation =&gt; ensure integrity of linear chromosomes =&gt; preventing DNA repair systems =&gt; mistaking the very ends of the DNA strand from a double-strand break. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L1) EFFECT OF BMI AND SEX =&gt; At most known + novel T2D-loci minimal differences in statistical significance +</td>
</tr>
<tr>
<td class="r data">9</td>
<td class="l data">Serum metabolite profile associated with incident type 2 diabetes in Koreans: findings from the Korean Genome and Epidemiology Study</td>
<td class="l data">(A) Amino acid + choline-containing phospholipid metabolisms altered in T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) Seven metabolites =&gt; hexose, valine + 5AA&#39;s in obesity + T2D =&gt; related to fat mass + obesity-associated (FTO) genotype. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) Altered metabolites =&gt; genetic loci =&gt; Korean T2D subjects =&gt; incident T2D over 8 year FU. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) GLYCEROPHOSPHOLIPIDS + SPHINGOMYELIN =&gt; phospholipid metabolism =&gt; incident T2D, specificity LysoPC (17:0 +18:2), 8PC aa metabolites, 2PC ae, DM(OH) 22:2 + SM 16:1 =&gt; significant predictors of T2D risk. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) Phospholipids PC + SM =&gt; dominant components of cellular membranes =&gt; signal transduction + constitute most lipoproteins. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) LysoPC 17:0 + 18:2 =&gt; -vely assoc. incident T2D LysoPC exclusively found in dairy foods =&gt; effective redn T2D risk. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) LysoPC =&gt; signalling molecule =&gt; atherogenic + inflammatory processes =&gt; mechn unknown. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) PC aa essential for the hepatic release of TG-rich VLDL. PC ae =&gt; antioxidant that inhibits lipoprotein oxidn. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) Previous studies =&gt; PC ae levels redn in obese or IR subjects. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Reduced SM synthesis =&gt; increased levels of ROS (reactive oxygen species) + reduced insulin secretion. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) LysoPC, PC + SM to T2D development =&gt; correlations with blood phenotype =&gt; altered choline-containing phospholipid metabolism =&gt; increased development of T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) ARIC study =&gt; 48 pairs sig. assoc. diet + metabolites esp. sugar rich foods + beverages assoc. metabolites related to oxidative stress + lipid profiles.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Dietary pattern + plasma urinary metabolites =&gt; O-acetylcarnitine + phenylacetylglutamine =&gt; +vely associated with different food groups =&gt; red meat + vegetable intakes respectively. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) Tested relationships =&gt; dietary quality + metabolites + T2D incidence =&gt; 22 metaboliotes =&gt; sig. predictors =&gt; incident T2D after controlling for covariates. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) Healthy diet =&gt; redn PC aa 32:1 level + increase SM(OH) XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) These metabolites were tested for negative assoc. dietary quality + T2D =&gt; each metabolite + dietary score =&gt; significant =&gt; combn BUT HR&#39;s attenuated. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) Better diet quality =&gt; redn future T2D risk, both dependently + independently of intermediate metabolites. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) Food intake + relevant nutrients =&gt; interact with gut microbiome =&gt; reflected in blood metabolites. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) Links between dietary intake, gut microbiota + metabolic markers + assoc. T2D =&gt; FURTHER INVESTIGATED. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) Consumption of PC containing foods =&gt; meat / eggs =&gt; increased T2D risk =&gt; bacterial transformation of PC =&gt; trimethylamine oxide (TMAO). XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (V) Ethnic differences important! =&gt; specific popns response to specific stimulus =&gt; chemicals + nutrients =&gt; dependent of gender + ethnicity =&gt; important for preventive strategy + p&#39;cological treatment of T2D. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (W) AA&#39;s, biogenic amines, spermine, hexoses + choline-containing phospholipid metabolism =&gt; incident T2D. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (X) Targeted metabolmic profiling =&gt; biochemical pathway of T2D pathogenesis. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Y) Covered metabolites =&gt; choline-containing phospholipids + structural similariites + metabolic interrelationships =&gt; hindered comprehensive assessment of metabolic alterations =&gt; T2D. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Z) Discovered metabolites =&gt; role to play in preventing controlling development of new onset T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (A1)LysoPC is a signaling molecule involved in atherogenic and inflammatory processes (49), of which the major function needs to be clearly elucidated. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B1) Given that food intake and relevant nutrients possibly interact with the environment and the gut microbiome, and that these interactions would be reflected in the blood metabolites, the links among dietary intake, gut microbiota and metabolic biomarkers and their associations with T2D must be further investigated. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C1) Because the response to the specific stimulus (e.g. chemicals, nutrients, etc.) can be distinct depending on gender and ethnic group (62), separate analysis in a certain population is required to apply the identified metabolites for planning the preventive strategy as well as for pharmacological targeting to treat T2D.</td>
</tr>
<tr>
<td class="r data">10</td>
<td class="l data">Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial</td>
<td class="l data">(A) Circulating BCAA&#39;s + AAA&#39;s =&gt; adverse outcomes in healthy people. Multiple circulating AA&#39;s =&gt; major vascular complications of diabetes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) Report of associations of AA&#39;s on macro-, microvascular + all cause mortality. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) Inverse association of tyrosine + risk of microvascular events independent of eGFR + urinary ACR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Association of high circulating BCAA&#39;s + AAA&#39;s =&gt; obesity known since 1960&#39;s =&gt; mediated by IR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) Insulin =&gt; regulator of branched chain a-keto acid dehydrogenase complex. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) IR =&gt; reduced BCAA catabolism, causal pathway is NOT unidirectional MR study =&gt; genetically elevated BCAA&#39;s (impaired catabolism) =&gt; increased T2D risk. Better understanding of underlying pathway needed. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) BCAA&#39;s =&gt; affect metabolism =&gt; suppressing postprandial glucose levels. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) Increased protein turnover =&gt; central obesity =&gt; increased higher circulating levels of AA&#39;s =&gt; also leads to increased AA&#39;s in overweight + T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (I) Mechns =&gt; circulating AA&#39;s =&gt; T2D + CVD. BCAA&#39;s =&gt; leucine, valine + isoleucine =&gt; no association with macrovascular events BUT low leucine + valine levels associated with all cause mortality. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) +ve asoc. independently predictive phenylalanine =&gt; CVD + all cause mortality. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (K) Further studies =&gt; high phenylalanine =&gt; adverse signal of CVD outcomes. XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX     (L) Genetic variants =&gt; instrumental variables for circulating AA&#39;s XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Genetic variants (SNP&#39;s / genotype / instrumental variables) &lt;===&gt; AA&#39;s (risk factor / phenotype) &lt;===&gt; outcomes (T2D / Obesity / CVD / all cause mortality). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Inverse association of tyrosine =&gt; risk of macrovascular events. Tyrosine positive association with baseline eGFR + inversely associated with baseline Hb1Ac + urinary ACR. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (N) Impaired conversion of phenylalanine to tyrosine =&gt; renal disease. Low tyrosine levels =&gt; impaired kidney function =&gt; predict microvascular events. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (O) Tyrosine =&gt; catecholamine synthesis XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (P) Metformin =&gt; lowers NOT raises tyrosine levels in CVD patients + high risk of T2D. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (Q) Effect of glucose lowering drugs on AA profiles in T2D =&gt; now of interest. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) Although the evidence from the present study suggests that these might only be very moderately useful biomarkers in incremental prediction of adverse events in individuals with type 2 diabetes, the pathophysiology underlying these associations and the possibility of intervention studies are intriguing and worthy of further investigation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) The causal pathway may not be unidirectional; a recent Mendelian randomisation study suggests that genetically elevated BCAAs (via impaired catabolism) are associated with increased risk of type 2 diabetes [34], although a better understanding of the underlying pathway is required to increase confidence in this observation [35]. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) Our data strongly support the need for further studies to determine why higher phenylalanine appears to be a consistently adverse signal for CVD outcomes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) That noted, counter-intuitively, we have reported that metformin in fact lowers, not raises, tyrosine levels in individuals with CVD and at high risk of diabetes [16]. The effect of other glucose-lowering drugs on amino acid profiles in individuals with diabetes would now be of interest. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (V) Further studies are now needed to validate our novel observations and to examine whether our findings may represent causal pathways. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (W) Most notably, the identification of tyrosine as a potential marker of microvascular risk requires further study. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">11</td>
<td class="l data">Identification of Neuroendocrine Stress Response-Related Circulating MicroRNAs as Biomarkers for Type 2 Diabetes Mellitus and Insulin Resistance</td>
<td class="l data">(A) Study identified =&gt; association =&gt; plasma expression of neuroendocrine stress response-related miRNA&#39;s + T2D + IR =&gt; occupational cohort. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) Differential miRNA expression profile + bioinformatic analysis =&gt; six stress-related miRNA&#39;s =&gt; (let-7b, let-7, miR-142, miR-144, miR-155 + miR-29a) associated with T2D =&gt; selected for qRT-PCR validation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) Average expression levels =&gt; let-7b, miR-142, miR-144 + miR-290 =&gt; significantly different between T2D vs healthy controls. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Increased expression of let-7b, miR-144 + miR-29a + decreased expression of miR-142 =&gt; significant-independent predictors of T2D, IFG, even IR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) ROC analysis =&gt; 3-miRNA panel =&gt; let-7b, miR-142 + miR-144 =&gt; high accuracy =&gt; diagnosing T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) miRNA =&gt; important signatures or therapeutic targets =&gt; T2D =&gt; in circulation + specific tissues. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) miR-184 =&gt; highly regulated miRNA =&gt; impacting growth + function of the B-cell. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) By targets Argonaute2, miR-184 plays an adaptive role of the miRNA pathway based on metabolic state. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) The Argonaute protein family, first discovered for its evolutionarily conserved stem cell function, plays a central role in RNA silencing processes as essential components of the RNA-induced silencing complex (RISC). RISC is responsible for the gene silencing phenomenon known as RNA interference (RNAi). Argonaute proteins bind different classes of small non-coding RNAs, including microRNAs (miRNAs), small interfering RNAs (siRNAs) and Piwi-interacting RNAs (piRNAs). XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Stress-induced overexpression of miR-708 suppressed B-cell proliferation + induced B-cell apoptosis =&gt; novel mechn of glucose regulation of B-cell function + growth. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) Comparing to tissue biomarkers =&gt; circulating miRNA&#39;s =&gt; preferred =&gt; easier sampling + testing. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) Circulating miR-192 + miR-193b =&gt; found significantly increased  =&gt; prediabetic state. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (M) Other miRNA&#39;s =&gt; biomarkers =&gt; diabetic complications =&gt; e.g. plasma miR-152 + diabetic nephropathy + miR-93 + diabetic retinopathy. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Circulating miRNA&#39;s =&gt; help predict the development + progression of T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) Increasing evidence =&gt; psychosocial factors facilitate the development + progression of central obesity + T2D =&gt; possibly as the results of increased IR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) Copenhagen Psychosocial Questionnaire =&gt; assess job-related psychosocial stress. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) After adjustment for influence of cortisol, HOMA-IR =&gt; significantly associated =&gt; scales of &quot;demands at work&quot; + &quot;insecurity at work&quot;. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) Psychosocial factors interact with biological mechns =&gt; several levels =&gt; neuroendocrine, metabolic + molecular responses. XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) Stress hormones influence glucose metabolism =&gt; stimulation gluconeogenesis + impairing glucose uptake in peripheral tissues like fat + muscle. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) Activation of stress hormones secretion =&gt; mediated by neuronal signals. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) Repeated stress =&gt; activates hypothalamic paraventricular nucleus to synthesize (corticotrophin release hormone) CRH =&gt; major regulator of stress responses. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (V) Anterior pituitary =&gt; responds to CRH =&gt; produces adrenocorticotropic hormone (ACTH) =&gt; released into circulation =&gt; promotes synthesis + release =&gt; glucocorticoids (cortisol in humans) =&gt; adrenals. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (W) HPA (hypothalamic-pituitary-adrenal) axis =&gt; controlling cortisol secretion + SNS (sympathetic nervous system) =&gt; originate from hypothalamus =&gt; interlinked + hyperactivity in one of them can activate the other. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (X) Our study =&gt; plasma levels of (epinephrine) E, (norepinephrine) NE, cortisol + CRH =&gt; significantly higher in T2D vs control (P&lt;0.05). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Y) Results =&gt; evidence association between chronic stress + T2D =&gt; occupational popn study. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Z) Elevated activites =&gt; HPA axis + SNS =&gt; triggered by psychosocial factors + reported in individuals with metabolic syndrome. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (A1) Increased plasma IL-6 levels in T2D + correlation of IL-6 with cortisol =&gt; evidence of the pathway between chronic stress + T2D =&gt; since various psychological stressors alone can induce proinflammatory. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B1) Cellular responsiveness =&gt; stress hormone =&gt; dependent on the amount of corresponding receptor protein. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C1) Significant upregulated expression of let-7b + miR-144 in T2D =&gt; our study =&gt; downregulated expression of their target gene =&gt; ADBR2 / ADBR3 (B-adrenoreceptors) + NR3C1 (GR) respectively. XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D1) Protein expression of ADRB3 was regulated by direct binding of let-7b at 3&#39;-UTR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E1) Let-7b =&gt; -vely correlated with ADRB3 protein level =&gt; decreased expression in perivascular adipose tissue of hypertensive mice. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F1) Cortisol treatment =&gt; decreased NR3C1 mRNA levels + increased miR-144 in T2D patients in hippocampus + sperm of mice. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G1) Evidence of NR3C1 as target of miR-144 =&gt; obtained from next generation sequencing (miRTarBase). XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H1) Positive correlation between let-7b + E/NE, miR-144 + cortisol =&gt; redn stress hormone receptor expression =&gt; reflects -ve feedback mechns =&gt; controlling the magnitude of responses to stress. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I1) Previous popn based study =&gt; chronic stress increase plasma cortisol =&gt; decreased mRNA expression of GRa + increased of GRB / GRa mRNA ratio in lymphocyte. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J1) miR-142 =&gt; mediated expression of CRH =&gt; lower levels =&gt; T2D or IFG vs controls. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K1) miR-142 =&gt; participants in the inflammatory response =&gt; regulating the prodn of IL-6. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L1) Plasma CRH + IL-6 =&gt; -vely associated with miR-142 expression in total subjects =&gt; explained by the inhibitory effect of miRNA on target genes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M1) Microarray analysis =&gt; downregulation miR-142 in the peripheral blood of mice =&gt; associated pronounced enhanced oxidative stress. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N1) miR-29a =&gt; reported to be involved inthe glucocorticoids signalling pathway + chronic academic stress =&gt; excessive glucocorticoids reduce =&gt; expression of miR-29a. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O1) Association may partially be explained by receptor gene NR3C1 + CRHR1. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P1) miR-29a expression =&gt; significantly associated with T2D + HOMA-IR =&gt; relatively weak correlations exist only between miR-29a + cortisol (r=0.183) in the total subjects. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q1) It is possible =&gt; miR-29a =&gt; regulates glucose metabolism throu</td>
</tr>
<tr>
<td class="r data">12</td>
<td class="l data">Metabolomics insights into early type 2 diabetes pathogenesis and detection in individuals with normal fasting glucose</td>
<td class="l data">(A) Popn-based prospective study =&gt; individuals with NFG at baseline =&gt; 95 progressed to T2D =&gt; FU period of 20 years. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) Information =&gt; discrete set of 19 metabolites associated with T2D incidence =&gt; improved the capability of predicting incident T2D beyond the predictions made using only the clinical risk factors obtained in routine care. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) Significant biological finding =&gt; enrichment in the nitrogen metabolism pathway =&gt; T2D risk. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Genetic approach =&gt; additional evidence =&gt; markers identified in the nitrogen metabolism pathway =&gt; glycine + phenylalanine =&gt; may be causal vs associative  =&gt; suggesting =&gt; alterations in this pathway + it&#39;s components =&gt; contribute to the earliest stages of T2D pathogenesis. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) Prior clinical metabolomics studies =&gt; focused =&gt; mixture of individuals =&gt; normoglycaemia + prevalent dysglycaemia =&gt; our study novel =&gt; study of participants =&gt; normoglycaemic =&gt; progressed to T2D. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) Studying individuals =&gt; progressed =&gt; normoglycaemia =&gt; T2D =&gt; eliminate confounding of our results by processes that occur in response to development of dysmetabolism (IFG or IGT). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) Main clinical finding =&gt; present study =&gt; metabolites substantially improved =&gt; ability to predict T2D beyond prediction achieved using conventional risk factors =&gt; individuals with normoglycaemia (based on fasting glucose). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) Our findings =&gt; slightly different vs previous metabolomics studies =&gt; not able to show that metabolites materially improved T2D risk prediction vs other clinical risk factors. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) Possible explanation =&gt; study popn =&gt; in normoglycaemia individuals, blood glucose + traditional T2D risk factors =&gt; may not be as strong predictors of future T2D vs those with dysglycaemia. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Novel risk factors =&gt; metabolites =&gt; stronger predictive capability.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) AUC of clinical risk factors in normoglycaemic individuals =&gt; &gt; 80% =&gt; slightly higher than reported in other recent studies. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) Suggests =&gt; differences in the length of FU or inclusion of different ethnic groups =&gt; affect the predictive capability of traditional T2D risk factors. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Another possible explanation =&gt; increased predictive ability of metabolites =&gt; related to the methodological approach implemented in this study. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Predictive capability observed in this study similar to predictive performance observed in recent studies using similar mechine learning approaches to prioritise metabolites. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) Normoglycaemic individuals included in this study =&gt; selected because =&gt; normal fasting glucose, normal glucose tolerance + HbA1c. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) Different, more stringent thresholds for &#39;normal&#39; =&gt; chosen (esp. subtle elevations in fasting glucose =&gt; those who developed T2D vs those who did not) =&gt; the data provide insight into early T2D pathogenesis among those currently considered clinically normoglycaemic. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) Convergence of selected metabolites =&gt; nitrogen metabolism pathway =&gt; serving as nitrogen donors =&gt; urea cycle =&gt; this pathway may influence the early pathogenesis of T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) Data =&gt; MR experiments =&gt; further support =&gt; components within this pathway =&gt; causal role in T2D development =&gt; confounding effects =&gt; obesity or lipid abnormalities =&gt; less likely. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) Our study =&gt; genetically increased glycine =&gt; reduced odds of T2D =&gt; consistent =&gt; previous epidemiological studies =&gt; directionality + effect sizes. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) Conflicts with previous MR analysis =&gt; no association =&gt; single genetic variant for glycine or glycine-serine ratio + diabetes-related traits. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) More precisely estimated effect sizes =&gt; using data from the largest metabolites meta-genome-wide association studies currently available + increase in the no of genetic variants used to proxy glycine here =&gt; explain the difference between these two MR studies. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (V) Phenylalanine =&gt; different studies =&gt; direct association between this metabolite + T2D risk, BUT no MR analysis for phenylalanine on T2D risk =&gt; yet conducted. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (W) Present study =&gt; particular biomarkers previously associated with T2D risk (e.g. TAG&#39;s (low carbon number) or 2-aminoadipate) =&gt; relevant even before initial glycaemic perturbations. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (X) In contrast =&gt; BCAA&#39;s associated with T2D incidence in previous studies =&gt; not prioritized by our selection algorithm. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Y) Our findings =&gt; highlight early metabolite changes in pathogenesis of T2D =&gt; consistent  =&gt; recent MR analysis finding =&gt; elevations in BCAA&#39;s occur after development of IR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Z) Results of our popn-based analysis =&gt; interpreted with caution =&gt; several limitations =&gt; unmeasured factors =&gt; (Changes in lifestyle factors, medications or insulin secretion  resistance over time) =&gt; influenced our findings. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (A1) MR approach =&gt; available for metabolites in the nitrogen metabolism pathway =&gt; partially mitigates this concern =&gt; suggests =&gt; genetically driven glycine + phenylalanine =&gt; related to risk of T2D independently of potential confounders. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B1) Our results =&gt; internally validated =&gt; not confirmed in a separate prospective cohort. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C1) Lack of independent validation =&gt; lack of availability of comparable cohorts of normoglycaemic individuals =&gt; developed T2D =&gt; necessary data were available. XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D1) Internal validation approach =&gt; 40% of the sample + running 100 iterations =&gt; allows us to rule out other potential confounding issues =&gt; e.g. compatibility between metabolomics platforms or available standards in libraries, even when similar platforms were used. XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E1) Five TAG&#39;s =&gt; prioritized by our methodological approach BUT did not find significant enrichment of pathways associated with these species. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F1) Reason for this =&gt; software used for pathway enrichment analysis =&gt; provide poor reporting for lipid classes + pathways OR because only 5 TAG&#39;s in a particular metabolic pathway =&gt; less likely than expected by chance for enrichment. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G1) Most prioritized metabolites correlate with baseline  clinical risk factors =&gt; BMI, 2h glucose, HOMA-IR, HDL-c + TAG&#39;s BUT associations of metabolites with T2D in normoglycaemic individuals remained after risk factor adjustment. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H1) Participants of study =&gt; European descent. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I1) Further work =&gt; our findings can be replicated by an independent cohort of same ethnicity + extend study =&gt; other racial / ethnic groups. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J1) CONCLUSIONS =&gt; study identifies a discrete set of metabolites that signal increased risk for T2D among normoglycaemic individuals =&gt; these metabolites involved + play causal role =&gt; early stage T2D pathogenesis. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K1) Last, we recognise that participants in this study were all of European descent. Further work is needed to determine whether our findings can be replicated in an independent cohort of the same ethnicity and to extend the study to other racial/ethnic groups. XXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">13</td>
<td class="l data">Evaluation of Two-Diabetes Related microRNAs Suitability as Earlier Blood Biomarkers for Detecting Prediabetes and type 2 Diabetes Mellitus</td>
<td class="l data">(A) Increase in incidence of prediabetes + rapid increase in T2D worldwide =&gt; urgent need =&gt; develop effective biomarkers =&gt; disease detection =&gt; early stage =&gt; facilitate preventative interventions + improve patient&#39;s care. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) microRNA&#39;s (miRNA&#39;s) =&gt; small non-coding RNA molecules =&gt; regulate important cellular processes + implicated in many pathological conditions. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) Release from cells =&gt; circulation =&gt; stalely detected in blood, miRNA&#39;s =&gt; promise =&gt; prognostic, diagnostic + predictive biomarkers. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Studies =&gt; our group + others =&gt; stability + utility of peripheral blood miRNA&#39;s as biomarkers for prediabetes, T2D + other diseases. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) Previous studies =&gt; aberrant expression of numerous miRNA&#39;s including miR-375 + miR-9 influence insulin signalling pathway, IR + play a major role in T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) miR-375 + miR-9 =&gt; previously reported =&gt; important regulators =&gt; insulin secretion + glucose homeostasis. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) Examined expression of the diabetes-related miR-375 + miR-9 =&gt; TaqMan-based RT-qPCR =&gt; peripheral blood of prediabetes patients =&gt; T2D patient + non-diabetic healthy individuals + evaluated =&gt; suitability =&gt; earlier blood biomarkers =&gt; detecting =&gt; prediabetes + T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) Findings =&gt; miR-375 expression =&gt; higher levels =&gt; prediabetic patients + progressively more enriched in T2D patient vs controls. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) Observation =&gt; miR-375 expression =&gt; significantly higher in T2D patients vs prediabetic patients. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) miR-9 expression was observed to be higher in T2D vs prediabetes BUT not significant. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) Increased expression of miR-375 + miR-9 in prediabetes + T2D patients =&gt; agreement with previous report =&gt; increased miR-375 + miR-9 in sera of patients =&gt; prediabetes + T2D. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) Our study =&gt; multivariate logistic regression analysis =&gt; crude adjusted models =&gt; direct association between miR-375 + miR-9 =&gt; presence of prediabetes + T2D =&gt; assocaition remained significant following adjustment for =&gt; age, sex, BMI, mean BP, HbA1c, total cholesterol, TG&#39;s + LDL. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Results =&gt; possible link between miR-375 + progression from prediabetes =&gt; T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) miR-375 + 9 =&gt; islet specific microRNA&#39;s =&gt; expressed high levels =&gt; during human pancreatic islet development =&gt; demonstrated that miR-375 =&gt; abundantly expressed in pancreatic B-cells + essential for maintaining normal pancreatic cell mass. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) miR-375 =&gt; -ve regulate of glucose-stimulated insulin secretion =&gt; controlling expression of myotrophin (Mtpn) + phospho-inositide-dependent protein kinase-1 (Pdk1) genes. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) overexpression of miR-375 =&gt; suppresses insulin secretion BUT downregulation enhances  insulin release. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) miR-375 =&gt; key player =&gt; regulation of insulin release + glucose homeostasis. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) miR-9 =&gt; regulates insulin secretion =&gt; effect on insulin exocytosis from the pancreas. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) Overexpression of miR-9 inversely correlates with glucose stimulated insulin release by directly targeting Onecut2 (OC2) =&gt; inhibits expression of Granuphilin / Slp4. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) Overexpression of OC2 suppress Granuphilin transcription. XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) Impaired insulin secretion + action =&gt; prediabetes + T2D. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (V) Metabolic abnormalities may precede T2D for years + high percentage of prediabetes patients will progress to clinical T2D. XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (W) Important regulatory roles of miR-375 + miR-9 =&gt; insulin secretion, upregulations of miR-375 + miR-9 in blood of prediabetes + T2D =&gt; observed in current study =&gt; further support earlier  suggestion =&gt; these two miRNA&#39;s =&gt; pathogenicity of T2D + miR-375 =&gt; assocated with T2D progression. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (X) Several epidemiological studies =&gt; age, obesity, dyslipidaemia, uncontrolled hyperglycaemia, hypertension + family history =&gt; increased risk of progression to T2D. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Y) Our study =&gt; miR-375 + miR-9 =&gt; significantly elevated in prediabetes + T2D =&gt; +ve correlations with FG + HbA1c in both groups. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Z) miR-375 + miR-9 =&gt; +vely correlated with mean BP + total cholesterol =&gt; prediabetes + T2D + miR-9 =&gt; +vely correlated =&gt; age + BMI. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (A1) Results =&gt; imply link between two miRNA&#39;s + susceptibility of developing T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B1) Animal studies of diabetes =&gt; increased circulating levels of miR-375 =&gt; useful predictor of diabetes + B-cell death. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C1) Present study =&gt; ROC curve analysis =&gt; miR-375 =&gt; discriminated between prediabetes + T2D patients from healthy subjects + differentiated between prediabetes + T2D patient =&gt; significant diagnostic ability. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D1) Previous study =&gt; significant increase in the expression of miR-375 in T2D patients =&gt; suggested possible use as a biomarker for T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E1) Elevated miR-375 expression =&gt; useful biomarker not only for T2D BUT for prediabetes patients at risk of developing T2D (our study). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F1) ROC analysis of our study =&gt; lower diagnostic value + borderline significance of miR-9 in discriminating between 3 subject groups =&gt; miR-9 =&gt; not a good biomarker for prediabetes + T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G1) Combn of miR-375 + miR-9 =&gt; enhances the predictability to discriminate prediabetes patient from healthy subjects + T2D patient from healthy subjects. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H1) Combined miR-375 + miR-9 =&gt; didn&#39;t significantly enhance predictability to discriminate prediabetes vs T2D. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I1) Increased miR-9 expression in prediabetes + T2D + correlation with T2D risk factors =&gt; suggests =&gt; association with susceptability to T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J1) Our study =&gt; blood miR-375 + miR-9 =&gt; expressed in high levels in prediabetes + T2D vs non-diabetic healthy subjects + progressively more enriched in T2D. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K1) Both miRNAs =&gt; directly associated with presence of prediabetes + T2D independently of known risk factors to T2D + miR-375 =&gt; independently associated with development of T2D. XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L1) miR-375 + miR-9 =&gt; +ve correlated with glycaemic status + other T2D risk factors =&gt; implying link between two miRNA&#39;s =&gt; susceptibility to developing T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M1) Our study =&gt; high diagnostic ability for miR-375 BUT not miR-9 =&gt; to distinguish overall patients from control + prediabetes from T2D patients WHEREAS combn of miR-375 + miR-9 =&gt; good diagnostic ability discriminate overall patients vs controls. Indicating miR-375 alone or in combn with miR-9 =&gt; biomarkers of early detection =&gt; prediabetes + T2D. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N1) Further validation studies in larger sample size are still needed before the clinical application miR-375 as a biomarker for prediabetes and T2D.</td>
</tr>
<tr>
<td class="r data">14</td>
<td class="l data">An Expanded Genome-Wide Association Study of Type 2 Diabetes in Europeans</td>
<td class="l data">(A) Large-scale study of T2D genetics =&gt; individual variants were assayed in up to 238,209 subjects =&gt; identified 13 novel T2D-associated loci at genome-wide significance + refined causal variant location for the 13 novel + 69 established T2D loci. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) Evidence of enrichment in regulatory elements at associated loci in tissues relevant for T2D + tissue specific enrichment in regulatory annotations when T2D loci were stratified according to inferred physiological mechn. XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) Present + recent analyses =&gt; total no of independent T2D associations =&gt; 128 distinct signals at 113 loci. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Lead single nucleotide variants (SNV&#39;s) at all 13 novel loci were common minor allele frequency (MAF &gt; 15%) + comparatable effect size (1.07 =&lt; OR =&lt; 1.10) =&gt; previously identified common variant associations. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) Associations =&gt; novel loci =&gt; homogeneous effects across diverse ethnicities =&gt; supporting =&gt; evidence for coincident common risk alleles across ancestry groups. XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) Conclude =&gt; misclassification of diabetes subtype not a major concern for these analyses =&gt; HLA-DQA1 signal =&gt; represents genuine association with T2D =&gt; independent of nearby signals that influence T1D. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) Observed  =&gt; general increase  =&gt; size of credible sets with 1000G imputation vs HapMap imputation. These are both imputation reference panels (IRP&#39;s). XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) Imputation methods attempt to identify haplotype sharing between individuals in the sample and in as IRP + use this information to infer the alleles at untyped loci in the sample. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) Imputation allows geneticists to study variants that have been directly genotyped in the sample + increase power + resolution of genome-wide association studies (GWAS). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) The increase in the size of credible sets =&gt; improved enumeration of potential causal common variants on known risk haplotypes vs resolution toward low-frequency variants of larger effect driving common variant associations. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) Findings =&gt; consistent with inference =&gt; T2D risk signals identified by GWAS are overwhelmingly driven by common causal variants. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) Imputation with denser reference panels in ethnically restricted samples =&gt; more complete elaboration of the allelic content of common risk haplotypes. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Finer resolution of those haplotypes =&gt; provide greater confidence  =&gt; location of causal variants =&gt; require further expansion of trans-ethnic fine mapping efforts. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Distinct signals =&gt; established CCND2 + TP53INP1 loci =&gt; point to contributions of low-frequency variant associations of modest effect =&gt; BUT larger samples needed =&gt; robustly detect association signals at low frequency. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) New large data sets =&gt; used to expand the follow-up of suggestive signals. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) Discovery of novel genome-wide significant association signals =&gt; current analysis =&gt; attributable to increased sample size vs improved genomic coverage. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) Queried a large proportion of the low-frequency variants present in the 1000G European reference haplotypes + &gt; 80% power to detect genome-wide significant with OR &gt; 1.8 =&gt; tested low-frequency variants =&gt; found =&gt; no low frequency variant associations =&gt; in established loci or novel loci. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) Low frequency variants coverage  =&gt; current study =&gt; not complete =&gt; adds to growing evidence =&gt; few low-frequency T2D risk variants =&gt; moderate to strong effect sizes =&gt; European ancestry samples =&gt; consistent =&gt; primary role =&gt; common variants =&gt; modest effect =&gt; T2D risk. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) Current study =&gt; re-inforces conclusions from a recent study =&gt; imputed from whole-genome sequencing data =&gt; from 2,657 European T2D case + control subjects rather than 1000G =&gt; into a set of GWAS studies partially overlapping with the present meta-analysis. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) Demonstrated =&gt; failure to detect low-frequency associations in that study =&gt; not overcome by a substantial increase in sample size. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) In this study =&gt; did not have sufficient imputation quality to test for T2D assocations with rare variants + cannot evaluate the collective contribution of variants with MAF &lt; 0.5% to T2D risk. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (V) Development of T2D =&gt; dysfunction of multiple mechns across several distinct tissues. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (W) When coupled with functional data =&gt; larger effect estimates for enrichment of coding variants than observed with HapMap SNV&#39;s alone =&gt; more complete recovery of the causal variants =&gt; imputation =&gt; denser reference panel. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (X) Function annotation analyses =&gt; stratification of T2D risk loci =&gt; primary physiological mechn =&gt; evidence for consistent + appropriate tissue-specific effects =&gt; transcription regulation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Y) Analyses =&gt; exemplify the use of combn of human physiology + genomic annotation to position T2D GWAS loci =&gt; respect to cardinal mechanistic components of T2D development. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Z) Extension of this approach =&gt; provides valuable in-silico strategy =&gt; aid prioritization of tissues =&gt; mechanistic characterization of gentic associations. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (A1) Hypothesis-free pathway analysis of T2D associations  =&gt; DEPICT =&gt; highlighted causal role of mTOR signalling pathway =&gt; etiology of T2D =&gt; not observed from indvidual loci associations. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B1) mTOR pathway =&gt; previously implicated =&gt; obesity, IR + T2D =&gt; cell + animal models. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C1) The current results emphasize that progressively larger sample sizes, coupled with higher density sequence-based imputation (13), will continue to represent a powerful strategy for genetic discovery in T2D and in complex diseases and traits more generally. At known T2D-associated loci, identification of the most plausible T2D causal variants will likely require large-scale multiethnic analyses, where more diverse haplotypes, reflecting different patterns of LD, in combination with functional (31,50,51) data allow refinement of association signals to smaller numbers of variants (2) XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">15</td>
<td class="l data">The Emerging Role of Metabolomics in the Diagnosis and Prognosis of Cardiovascular Disease</td>
<td class="l data">(A) Metabolomics is used to improve diagnosis + prognosis of various CVD&#39;s, but CVD&#39;s have co-morbidities =&gt; kidney disease, hepatic steatosis + obesity and/or T2D. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) Obesity + T2D =&gt; add extreme complexity to the  understanding the metabolomic profile because these conditions result in =&gt; significant pathology + perturbed metabolism in other peripheral tissues =&gt; (skeletal muscle, liver, adipose tissue) =&gt; which contribute to the circulating metabolomic profile in patient with CVD.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) IR =&gt; feature of obesity + T2D =&gt; metabolomic profiling obese / T2D =&gt; increased lactate levels =&gt; suggest increased anaerobic glycolysis =&gt; non-consistent with IR which impairs glucose metabolism. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (D) Numerous studies =&gt; tight correlation =&gt; circulating BCAA&#39;s =&gt; IR + T2D. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) Metabolic profiling =&gt; implicates BCAA&#39;s =&gt; obesity + IR =&gt; BCAA&#39;s + AAA&#39;s predictors of future T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) Generation of amino acid score =&gt; (isoleucine, phenylalanine + tyrosine) =&gt; significantly T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) Impaired myocardial BCAA / (Branched chain keto acids) BCKA metabolism in HF =&gt; important to understand how circulating BCAA profile in obesity reflects deranged systemic + myocardial metabolism. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) Metabolomic profiling technologies have significantly evolved to a point where high-resolution and high-throughput assessment of thousands of metabolites within a biological sample can be performed with relative ease.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) Due to the expansive biochemical diversity of metabolites within the human metabolome, several complementary platforms and techniques are necessary for comprehensive metabolic characterization. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) These techniques, MS and NMR coupled with LC or gas chromatography, are exquisitely sensitive, generating the metabolic fingerprint of a biological sample that not only reflects the condition of interest, but also diet, drug effects, sex, and other comorbidities and exposures. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (K) Thus, human metabolomic studies are consequently prone to clinical confounding factors that may lead to spurious diagnoses / conclusions. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) Yet the application of metabolomic profiling to several large population-based epidemiological cohorts has allowed for robust statistical adjustment for potential confounders, and has resulted in externally reproducible findings. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (M) In addition, metabolomics has been applied in smaller studies of unique clinical scenarios that allow for serial sampling before and after a controlled biological perturbation (e.g., exercise testing, planned MI, drug administration, and so on). Such paired experiments allow subjects to serve as their own controls, mitigating the risk of confounding factors. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (N) In addition, emerging investigational techniques are integrating metabolomics with other “omics” platforms in order to gain insight into pathophysiological interactions of metabolites, proteins, genes, and disease states. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) Furthermore, the state-of-the-art metabolomic technologies now available provide us with a snapshot of the metabolic fingerprints of individual patients, which can serve as diagnostic and/or prognostic tools that can be used to identify impairments in systemic or myocardial metabolism occurring during the development and worsening of CVD, as well as identifying the types and timing of specific interventions / therapies. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) Thus, metabolomics is a powerful technology that is transforming our ability to predict, detect, and understand a myriad of cardiometabolic disease states, and to monitor the effectiveness of therapeutic interventions. In doing so, metabolomics continues to advance our societal objective of personalizing the practice of medicine.</td>
</tr>
<tr>
<td class="r data">16</td>
<td class="l data">Adiponectin, Insulin Sensitivity, β-Cell Function, and Racial/Ethnic Disparity in Treatment Failure Rates in TODAY</td>
<td class="l data">(A) Present investigation of racial / ethnic contrast in adiponectin, insulin sensitivity + B-cell function in TODAY at randomization + over time =&gt; demonstrates; XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX 1. NHB =&gt; significantly lower total adiponectin, high molecular weight adiponectin (HMWA) + HMWA-to-total adiponectin ratio at baseline vs other groups. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX 2. Treatment-associated change in HMWA over time =&gt; significantly different among the 3 racial groups  + lower percentage increase over the first 6 months in NHB. XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX 3. Early change in HMWA =&gt; 1st 6 months of treatment =&gt; significant independent predictor of progression to glycaemic failure. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX 4. Baseline HMWA =&gt; did not predict glycaemic failure =&gt; NOR was it different between those who failed vs did not fail treatment. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX 5. Treatment-associated change in total + HMWA =&gt; significantly lower =&gt; those that failed treatment vs those who did not fail =&gt; irrespective of race / ethnicity. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  6. No racial / ethnic-related differences in insulin sensitivity + B-cell function at baseline + over time. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (C) TODAY study =&gt; obese youth + T2D =&gt; randomly assigned =&gt; metformin alone, metformin + rosiglitazone or metformin + lifestyle =&gt; glycaemic failure rates =&gt; higher in NHB (52.8%) vs NHW (36.6%) + H (45.0%) =&gt; race / ethnicity alone =&gt; significant effect beyond the treatment effect. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Racial / ethnic disparity =&gt; higher HbA1c in black vs white youth with T2D =&gt; reported in paediatric diabetes clinic. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) To probe the metabolic / hormonal mechns =&gt; potentially responsible for the racial / ethnic disparity =&gt; therapeutic failure rates in TODAY, we targeted; XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX 1. Adiponectin =&gt; because it is known to vary by race / ethnicity. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX 2. Insulin sensitivity + B-cell function =&gt; well-established racial / ethnic contrast. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) Adiponectin has anti-diabetic properties =&gt; suppresses hepatic glucose output + lowers systemic glucose concns, stimulates skeletal muscle glucose uptake + promotes B-cell function + survival. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) Adiponectin concns =&gt; low  in obesity + states of IR, T2D + CVD. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) Adiponectin levels =&gt; youth T2D =&gt; significantly lower vs equally obese peers without diabetes + correlate +vely =&gt; insulin sensitivity + 1st phase insulin response + -vely with =&gt; proinsulin =&gt; insulin ratio in youth with / without diabetes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (I) Adiponectin levels =&gt; prognostic value for diabetes course beyond currently recognized set of risk factors. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Racial / ethnic differences =&gt; adiponectin =&gt; previously described =&gt; youth + adults. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) NHB youth =&gt; signifcantly lower adiponectin concns vs white peers =&gt; irrespective of adiposity. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) Studies of HMWA =&gt; similar racial / ethnic contrasts =&gt; adults. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Current study =&gt; NHB youth + T2D =&gt; significantly lower total adiponectin + HMWA concns =&gt; at time of randomization =&gt; TODAY =&gt; post-adjustment for higher BMI in NHB. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Additional novel findings =&gt; HMWA-to-total adiponectin ratio =&gt; significantly lower in NHB vs other two groups. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) Baseline adiponectin =&gt; did NOT provide any prognostic value =&gt; glycaemic failure. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (P) Baseline adiponectin =&gt; neither predictor of glycaemic failure in Cox proportional hazards analysis NOR were baseline adiponectin levels different between failed vs not failed. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) Adiponectin levels in adults increase with treatment of diabetes + effect more pronounced with thiazolidiones. XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) Rosiglitazone =&gt; 4 - 8 mg/day =&gt; adiponectin levels increase by =&gt; 50 - 200% after 3 - 6 months in adults  with T2D =&gt; improvements in glycaemic control + insulin sensitivity. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) Metformin treatment in adults with T2D =&gt; most but not all studies =&gt; no change in adiponectin levels. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) Diabetes Prevention Program (DPP) =&gt; metformin intervention in impaired glucose tolerant adults =&gt; associated with a significant increase in adiponectin from baseline to 1 year. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) Results on the effect of metformin treatment =&gt; adiponectin concns in youth =&gt; contradictory. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (V) Some studies =&gt; no change in obese IR normoglycaemic adolescents =&gt; other studies =&gt; increases after 3 months of metformin 850 mg BD in youth with impaired glucose tolerance. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (W) Trials combining metformin with lifestyle intervention in obese children + normal glucose tolerance =&gt; increase in adiponectin levels =&gt; after 3 + 6 months. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (X) Studies in youth + T2D =&gt; change in adiponectin associated with metformin + thiazolidinedione =&gt; lacking. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Y) Present investigation =&gt; total adiponectin + HMWA increased during the first 6 months in 3 racial / ethnic groups. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Z) Metformin + rosiglitazone group =&gt; significantly larger increases over time vs metformin alone + metformin + lifestyle groups. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (A1) This is in agreement with observations =&gt; adult T2D =&gt; consistent increases in adiponectin with rosiglitazone or thiazolidinedione treatment =&gt; not necessarily the case with metformin. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B1) This investigation =&gt; important observation =&gt; treatment associated changes in HMWA =&gt; proportional to the effectiveness of treatment in preventing glycaemic failure (HR 0.55 total cohort, 0.52 in NHB, 0.58 in H + 0.63 in NHW). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C1) Proportional hazards modelling =&gt; changes in total adiponectin + HMWA =&gt; remained significant determinants of progression to glycaemic failure, even after adjustment =&gt; baseline HbA1c + oDI =&gt; important determinants of glycaemic failure. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D1) Treatment associated change in total adiponectin + HMWA =&gt; significantly lower =&gt; failed treatment vs not failed. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E1) Metformin + rosiglitazone group =&gt; larger increases in HMWA over time vs metformin alone + metformin + lifestyle groups =&gt; further support TODAY main outcome =&gt; combn of metformin + rosiglitazone  =&gt; superior to metformin =&gt; sustaining durable glycaemic control =&gt; glycaemic failure rates 38.6% vs 51.7% metformin vs 46.6% metformin + lifestyle. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F1) Collectively =&gt; novel observations =&gt; underscore =&gt; utility of adiponectin in youth T2D =&gt; biomarker of treatment response =&gt; predictive of glycaemic efficacy consistent with adult data. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G1) Combined with the discovery =&gt; increase in HMWA =&gt; significantly lower in NHB vs H + NHW =&gt; provides explanation =&gt; higher therapeutic failure rates in NHB vs two other racial groups. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H1) Remaining question =&gt; lower increase in HMWA in NHB =&gt; biological / genetic phenomenon OR inadequate treatment adherence. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I1) Adherence to the medn regimen =&gt; defined by =&gt; pill count =&gt; did NOT differ by race / ethnicity</td>
</tr>
<tr>
<td class="r data">17</td>
<td class="l data">Effect of Insulin Resistance on Monounsaturated Fatty Acid Levels: A Multi-cohort Non-targeted Metabolomics and Mendelian Randomization Study</td>
<td class="l data">(A) Bile acid, glycerophospholipid + caffeine metabolism assoc. with IR + FA biosynthesis =&gt; related to impaired insulin secretion. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) Discovered + replicated causal effects of IR on reduced mono-unsaturated FA, FA&#39;s (palmitoleic) POA + (Oleic acid) OA + suggestive evidence =&gt; higher levels of AAA =&gt; tyrosine. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) Sensitivity analysis =&gt; no pleiotropic of the genetic instruments. XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Causal effects =&gt; largely unaffected =&gt; exclusion of prevalent diabetes cases. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) All IR-increasing conditions =&gt; associated with downregulation of SCD-1 (rate-limiting enzyme MUFA biosynthesis) =&gt; redn in prodn of endogenous OA + POA. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) Palmitic + Stearic acid (SFAs) =&gt; SCD-1 introduces double bonds =&gt; POA (16:1n-7) + OA (18:1n-9) respectively =&gt; major precursors of cholesteryl esters (CE&#39;s) + triglycerides (TG&#39;s) =&gt; packaged =&gt; very low density lipoprotein (VLDL) particles =&gt; secreted by the liver. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) Reduced SCD-1 activity =&gt; adverse vascular outcomes : inhibition of SCD-1 in hyperlipidaemic mice =&gt; increased aortic atherosclerosis despite protective effects on obesity + IR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) Reduced SCD-1 activity =&gt; enrichment of SFA in VLDL + LDL =&gt; atherogenesis =&gt; macrophage-induced vascular inflammation. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) Competing effects on vascular + metabolic health. IR =&gt; reduced SCD-1 activity =&gt; counteracts the metabolic consequences of IR by improving insulin signalling BUT concomittently =&gt; increased risk of CVD =&gt; increased SFA =&gt; proinflammatory changes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) IR +vely associated with OA + POA, in contrast -ve genetic associations in MR studies. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) Molecular mechns =&gt; reduced tyrosine catabolism =&gt; IR-induced oxidative stress =&gt; increased methionine, cysteine + glutathione (anti-oxidant) =&gt; tyrosine hydroxylase inhibition. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) Molecular mechns =&gt; inactivation of tyrosine aminotransferase. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Causal effect of IR on circ OA + POA + tyrosine levels =&gt; new insights into metabolic signature of IR + impaired insulin secretion. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Potential implications =&gt; presumed IR-induced inhibition of MUFA biosynthesis =&gt; health outcomes =&gt; form part of explanation for elevated CVD risk in IR =&gt; independent of T2D development. XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (O) Future studies =&gt; hypothesized but untested relationship with cardiovascular disease requires further investigation. The effect of IR =&gt; elevated tyrosine =&gt; non-significant tendency in all cohorts =&gt; reached nominal significance after =&gt; combn of estimates in meta-analysis =&gt; Future studies =&gt; considerable risk of result being false +ve due to multiple testing =&gt; further investigation in larger MR studies (not been reported before). Associations between worse IR / T2D risk + circulating tyrosine levels =&gt; established in observational + longitudinal studies (42, 43) XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) Speculation =&gt; the identified association between tyrosine + increased T2D risk =&gt; due to concomitant IR =&gt; observed trends need to be confirmed through larger samples. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) Relative circulating levels =&gt; POA + OA =&gt; unlikely to reflect endogenous biosynthesis. Further experimental investigation =&gt; exact contributions of SCD-1, exogenous source, catabolism + excretion.</td>
</tr>
<tr>
<td class="r data">18</td>
<td class="l data">Early Prediction of Developing Type 2 Diabetes by Plasma Acylcarnitines: A Population-Based Study</td>
<td class="l data">(A) Applying a MS-based acylcarnitine profiling platform =&gt; panel of acylcarnitines =&gt; esp. assoc. future risk of T2D =&gt; substantially improved predictive ability for incident T2D beyond conventional risk, inc BMI + fasting glucose. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) Previous studies =&gt; obese + diabetic animal models =&gt; links of acylcarnitines =&gt; mild FAO dysregulation + mitochondrial stress =&gt; worsened IR + glucose deterioration. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) Treating myotube + acylcarnitine =&gt; Akt phosphorylation + glucose uptake in response to insulin stimulation. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Redn of mitochondrial FA import or acylcarnitine synthesis =&gt; alleviate lipid-induced IR =&gt; lipid-induced  =&gt; mitochonrial stress =&gt; predates the emergence of glucose deterioration + diabetes. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) Previous studies =&gt; acylcarnitine profiles, associated with insulin sensitivity, plus sig. different acylcarnitine profiles =&gt; normal glucose tolerance (NGT), prediabetic (impared glucose tolerance (IGT) +/- impaired fasting glucose (IFG)) + T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) Several prospective studies =&gt; medium and / or long-chain acylcarnitines =&gt; predicted cardiovascular events or mortality in &gt; 85 years or selected patients undergoing cardiac catheterization or dialysis. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) European studies targeted BIOCRATES metabolomics platform =&gt; no sig. assoc acylcarnitines + incident T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) Differences in =&gt; study design methodology + statistical analyses + ethnic differences + lifestyle =&gt; explain discrepancy between our study + others. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) Current study =&gt; selected acylcarnitines added to predictive models =&gt; substantially improved predictive ability =&gt; T2D beyond conventional risk factors e.g. BMI + fasting glucose (AUCs: 0.89 vs 0.73). XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Simple alternative approach =&gt; assess mitochondrial FAO dysregulation in vivo =&gt; specific acylcarnitine patterns =&gt; promising early biomarkers =&gt; T2D =&gt; long chain acylcarnitines =&gt; increased incident T2D. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) Long chain FA&#39;s =&gt; oxidized predominately inside mitochondrion. XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) LCFA&#39;s =&gt; transported across the mitochondrion inner membrane as long-chain acylcarnitine. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Initial metabolites of B-oxidn =&gt; accumulation of long chain acylcarnitine =&gt; reflect severe conditions of FAO dysregulation + mitochondrial overload + impaired tricarboxylic acid (TCA) cycle. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Obese + T2D subjects =&gt; increased non-esterified + long-chain acylcarnitines vs non-case subjects. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) Underlying mechn unclear =&gt; in-vitro studies =&gt; treatment with long chain acylcarnitines =&gt; induced IR + oxidative stress in human myotubes + regulated calcium efflux in cardiac tissue + Human Ether-a-go-go-Related Gene (hERG) channels in renal cells. Potential functional roles =&gt; LCFA derivative =&gt; beyond biomarkers of mitochondrial dysfunction. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (P) The associations of medium-chain acylcarnitines + T2D remain uncertain, explanations could include, different precursors or metabolic compartments that are involved =&gt; generation of medium-chain acylcarnitines which could be later B-oxidn metabolites of LCFA or directly esterified derivatives from MCFA. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) MCFA&#39;s =&gt; pro-inflammatory agents in some studies in-vitro, BUT antimicrobial, anti-inflammatory agents in other studies in-vivo + in-vitro. MCFA&#39;s in metabolic disorders =&gt; remains to be elucidated. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) Increased circulating 3-dehydroxycarnitine + 3-dehydrocarnitine =&gt; precursors of L-carnitine prodns =&gt; assoc lower risk incident T2D. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) Previously, carnitine, improves insulin-stimulated glucose utilization + T2D-related metabolic disorders =&gt; humans + rodents. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) Mechn =&gt; unclear =&gt; admin of 3-dehydroxycarnitine =&gt; mouse model lacking L-carnitine transporter =&gt; improved FA metabolism =&gt; potential benefits =&gt; carnitine precursors =&gt; maintaining energy homeostasis. XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) Findings =&gt; dicarboxylic acid acylcarnitines with odd chains or even chains =&gt; different impacts on the development of T2D. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (V) Malonylcarnitine (C3DC) =&gt; indicator =&gt; reflect malonyl-CoA levels. Malonyl-Co-A =&gt; key regulators =&gt; mammalian energy homeostasis =&gt; inhibiting mitochondrial CPT1 + FAO. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (W) IR-patients with obesity + T2D =&gt; high muscle malonyl-Co-A concns. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (X) Remains unclear whether malonyl-CoA accumulation =&gt; indicated by accumulated C3DC =&gt; serves as a feedback signal =&gt; suppress B-oxidn + mitochondrial stress =&gt; blocking CPT1 activity =&gt; to counteract lipid-induced IR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Y) +ve C3DC-diabetes assoc. in our study =&gt; role of malonyl-CoA =&gt; diabetes pathogenesis. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Z) Unlike odd-chain dicarboxylic acids, even chain dicarboxylic acids =&gt; derived from v-oxidn of FA&#39;s thereafter =&gt; B-oxidn. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (A1) Intervention studies =&gt; sebacic acid (C10DC FA) + dodecanedioic acid (C12DC FA) =&gt; favourable impacts on glycaemic control + energy utilization =&gt; T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B1) Inverse assoc. of C10DC + C12DC acylcarnitines =&gt; incident T2D =&gt; supported potential benefits of sebacic acid + dodecanoic acid in T2D. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C1) Elastic net model =&gt; successful =&gt; predictive accuracy + sparsity =&gt; high-dimensional data sets =&gt; used in variable selection + model selection.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D1) Acylcarnitines =&gt; sig. improved predicting power of T2D vs conventional risk factors =&gt; potential utility =&gt; novel early predictors of T2D risk assessment. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E1) These findings need to be replicated in other populations, and underlying biological mechanisms should be elucidated in future studies. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">19</td>
<td class="l data">Adiponectin levels predict prediabetes risk: the Pathobiology of Prediabetes in A Biracial Cohort (POP-ABC) study</td>
<td class="l data">(A) Biracial cohort =&gt; healthy offspring of patients with T2D =&gt; inverse association =&gt; adiponectinaemia (normal levels) =&gt; risk of incident prediabetes / diabetes =&gt; during longitudinal FU. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) Initially normoglycaemic persons =&gt; increase 5ug/dl higher baseline plasma adiponectin level =&gt; 40% lower rate of progression =&gt; prediabetes / diabetes, 2.6 years of FU. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) 110 participants =&gt; end point (prediabetes) =&gt; 10 participants =&gt; progressed T2D (100 participants =&gt; prediabetes). XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Well-known ethnic + geneder differences in plasma adiponectin levels =&gt; present study. Association of adiponectin status + incident prediabetes =&gt; consistent across gender + ethnicity =&gt; African-Americans (AA) + European-Americans (EA). =&gt; parental history T2D. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) Point estimates =&gt; reduced risk for prediabetes =&gt; same order of magnitude in black + white offspring (0.44 + 0.48 respectively) =&gt; 95% CI wider in whites. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) Adjustment for BMI =&gt; increases adiponectin-associated OR =&gt; prediabetes from 0.48 =&gt; 0.61 + wider 95% Cl. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) Observation =&gt; nominal redn = 40% in risk of incident prediabetes =&gt; despite adjustment for BMI =&gt; redn prediabetes risk assoc. with higher baseline adiponectin levels =&gt; partly mediated =&gt; adiposity related mechns. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) Previous cross-sectional + longitudinal studies =&gt; low adiponectin levels =&gt; increased risk of T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) Prospective Diabetes Prevention Programme (DPP) =&gt; patients with prediabetes =&gt; increased 3ug/ml baseline adiponectin levels =&gt; predicted 20-40% lower risk  =&gt; T2D in 3 year FU. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Approx 5ug/ml (1SD) higher baseline adiponectin levels =&gt; 40%lower risk of progression from normoglycaemia =&gt; prediabetes. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) Association of adiponectin with diabetes risk =&gt; evident of earlier stage in the pathogenesis of dysglycaemia. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) Ability =&gt; maintain high adiponectin prodn =&gt; protective of dysglycaemia in high risk of T2D. Hypoadiponectinaemia =&gt; risk factor  =&gt; initiation of early glucose abnormalities =&gt; predibetes / diabetes. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Favourable cardiometabolic profile of adiponectin =&gt; emerged since discovery.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N)  Mechns =&gt; not fully understood how adiponectin exerts it&#39;s favourable cardiometabolic effects. BUT could involve =&gt; improvement of insulin action, redn inflammatory tone, interaction with fibroblast growth factor (FGF)-21 + amelioration of lipotoxicity. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) Rodent models =&gt; overexpression of adiponectin =&gt; several beneficial effects =&gt; increased metabolic flexibility, redn in inflammatory markers, redn steatosis, improved insulin sensitivity, redn apoptosis + preservation of B-cell function. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) Interaction between adiponectin + FGF21, a potent regulator of metabolism + energy utilization. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) FGF-21 =&gt; redn blood glucose levels + increased insulin sensitivity in mouse models of obesity + IR =&gt; upregulation of adiponectin expression. X XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) FGF-21 =&gt; clearance of toxic ceramides in obese animals + adiponectin-knockout mice =&gt; refractory to ceramide-lowering effects of FGF-21. XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) Adiponectin =&gt; critical mediator =&gt; favourable metabolic + insulin sensitizing effects FGF21. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) Improvement in insulin sensitivity with PPAR-y agonists =&gt; mediated, in part =&gt; upregulation of adiponectin expression. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) Intervention that increased adiponectin levels =&gt; attractive candidates =&gt; clinical trials =&gt; diabetes prevention + improvement =&gt; cardiometabolic health. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (V) Interactions =&gt; increased adiponectin levels =&gt; exercise, weight loss, smoking cessation + treatment with PPAR-y agonists, PPAR-a agonists, ACE inhibitors + angiotensin 2 receptor blockers. All these interventions =&gt; favourable glucoregulatory outcomes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (W) Prediabetic participants =&gt; lifestyle intervention arm in DPP =&gt; increased circ adiponectin levels =&gt; 58% relative risk redn in incident diabetes vs placebo group. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (X) Cross-sectional + longitudinal studies =&gt; low adiponectin levels =&gt; prevalent T2D, impaired glucose homeostasis =&gt; unfavourable cardiometabolic profile. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Y) AA&#39;s + EA&#39;s =&gt; parental history of T2D =&gt; enrolled in POP-ABC study, baseline adiponectin levels =&gt; inversely related =&gt; risk of incidient prediabetes.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Z) Predictive relationship evident =&gt; despite gender + ethnic differences in baseline adiponectin levels. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (A1) Interventions =&gt; increased adiponectin levels =&gt; protection against the risk of dysglycaemia regardless of gender or ethnicity. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B1) The mechanisms whereby adiponectin exerts its favorable cardiometabolic effects are not fully understood, but could involve improvement in insulin action, decreased inflammatory tone, interaction with fibroblast growth factor (FGF)-21 and amelioration of lipotoxicity, among others. (34–39) XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">20</td>
<td class="l data">Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity: A Comprehensive Review</td>
<td class="l data">(A) Global challenges =&gt; diet-related obesity, T2D + CVD =&gt; enormous health + economic burdens =&gt; imperative of prioritizing nutrition in clinical care, advocacy, research + policy. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) Scientific advances =&gt; new evidence =&gt; key dietary priorities =&gt; cardiometabolic health. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) Food-based priorities =&gt; more fruits, non-starchy vegetables, nuts, legumes, fish, vegetable oils, yoghurt + whole grains + fewer red meats, processed (sodium-preserved) meats + food higher in refined carbohydrates + salt. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Redmeats minimized to prevent diabetes, butter used occasionally + other foods (e.g unprocessed poultry, eggs) consumed in moderation. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) Coffee + tea =&gt; can be enjoyed =&gt; possible (not confirmed) benefits + alcohol =&gt; if consumed =&gt; moderate  1 drink / day for women + 2 drinks / day for men. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) Harmful additives =&gt; sodium, transfat + added sugar =&gt; should be lower, + minimised through policy actions. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) Growing evidence + consensus =&gt; food based dietary patterns =&gt; best means to reduce CVD, obesity + weight gain + diabetes =&gt; replacing outdated emphasis on total fat, other isolated nutrients or calorie counting. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) Clinical behavior change efforts, health system changes, novel technologies, and robust policy strategies must complement and facilitate these individual food choices, which together will reduce cardiometabolic disease and economic burdens across the population.</td>
</tr>
<tr>
<td class="r data">21</td>
<td class="l data">Diabetes risk and amino acid profiles: cross-sectional and prospective analyses of ethnicity, amino acids and diabetes in a South Asian and European cohort from the SABRE (Southall And Brent REvisited) Study</td>
<td class="l data">(A) Novel ethnicity-specific data =&gt; associated AA + incident diabetes =&gt; 19 year FU. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (B) +ve association =&gt; baseline BCAA&#39;s =&gt; tyrosine + alanine + incident diabetes in middle-aged European men. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) South Asian men =&gt; same AA&#39;s + phenylalanine =&gt; strongly associated  =&gt; incident diabetes vs Europeans XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (D) Tyrosine + combn BCAA&#39;s + AAA&#39;s =&gt; strongly associated =&gt; incidence diabetes after multivariable adjustment in South Asian men. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (E) Adjustment for tyrosine =&gt; small (5%) contribution to explaining the ethnic difference in incidence of T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) Cross-sectional association at baseline AA&#39;s + markers of IR + glycaemia =&gt; followed patterns observed for incident diabetes =&gt; exception histidine =&gt; minimally associated with markers of IR in South Asian men. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (G) Association BCAA&#39;s + obesity =&gt; present BUT weaker in South Asian vs European. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX X (H) Consistent with obesity =&gt; weaker attentuation of AA&#39;s association + incident diabetes =&gt; suggests =&gt; conventional measures may not capture the best indicators of diabetes risk in South Asians. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) Other studies =&gt; strong associations in South Asians + Chinese men of low body weight =&gt; IR + BCAA&#39;s + AAA&#39;s =&gt; combn =&gt; isoleucine, leucine, phenylalanine, tyrosine + methionine. The association are independent of dietary protein intake + BMI. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (J) Cross-sectional finding =&gt; weaker association of obesity + BCAA&#39;s in South Asian men =&gt; increase AA levels =&gt; driven by IR more than obesity in South Asians + measures of obesity less satisfactory in this popn. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) Small cross-sectional study (age 35 -45 years) Indian Asians in India =&gt; strong correlations of isoleucine, leucine + phenylalanine + obesity in people with high BMI =&gt; with / without T2D. Lower correlations =&gt; low BMI + no T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (L) No comparator group =&gt; cannot compare relative strength of correlations. XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Findings of SABRE study closely associated with Framingham random cohort. European SABRE participants comparable baseline levels =&gt; glucose, insulin + obesity =&gt; younger, less likely to be hypertensive  + decreased tiacylglycerol levels =&gt; explains =&gt; weak associations of AA&#39;s + incident diabetes vs Framingham random cohort. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (N) South Asian SABRE participants =&gt; younger + more centrally obese =&gt; increased fasting glucose + insulin levels =&gt; experienced similar triacylglycerol levels + reduced BP vs Framingham random cohort. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (O) Association of AA&#39;s + incident T2D in South Asians closely resembled stronger association =&gt; Framingham replication cohort + Framingham high risk propensity matched cases + controls =&gt; despite lower overall obesity (BMI). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (P) Possible Mechns =&gt; BCAA&#39;s + AA&#39;s =&gt; validated previous findings =&gt; BCAA&#39;s + related metabolites =&gt; independently associated extremes of CAD severity, after adjusting for diabetes + measures of IR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (Q) Abdominal adipose tissue in South Asian individuals contains larger and more dysfunctional adipocytes [37]. It has also been suggested that increased AA levels may result from increased protein turnover in association with increased central obesity and reduced lean body mass [7]; this is a plausible, but untested, explanation for the increased levels of isoleucine, tyrosine, alanine and glutamine seen in our more centrally obese South Asian men. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) Further research is needed to understand the role of diet in the relationship between serum AA levels and risk of diabetes XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">22</td>
<td class="l data">Comparative study of glucose homeostasis, lipids and lipoproteins, HDL functionality, and cardiometabolic parameters in modestly severely obese African Americans and White Americans with prediabetes: implica</td>
<td class="l data">(A) African Americans (AA&#39;s) experience T2D + CV morbidity + mortality disproportionately more vs White Americans (WA&#39;s). XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) Exact contributions of obesity =&gt; T2D + CHD in AA&#39;s remain debatable. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) Whether severe obesity =&gt; differentially modifies the metabolic mediators + precursor&#39;s of pre-diabetes + T2D + CVD in AA&#39;s + WA&#39;s =&gt; remains to be investigated. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Increased epidemic of obesity =&gt; impact on glucose regulation, prediabetes + T2D =&gt; US ethnic + racial popns =&gt; comprehensive assessment of clinical + metabolic characteristics =&gt; modestly severe obese AA&#39;s vs WA&#39;s with prediabetes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) BMI &gt;30kg/m2 + prediabetes =&gt; &gt; Class III obesity + mean BMI &gt; 35kg/m2 + lean body fat &gt; 40% in both groups. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) BMI + % body fat greater in AA&#39;s vs WA&#39;s with prediabetes. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (g) Pathogenic Mechns =&gt; prediabetes, impaired glucose + T2D =&gt; abnormalities B-cell secretion, hepatic glucose prodn + glucose disposal (insulin-mediated [Si] + non-insulin-mediated [Sg + GEZI] glucose disposal) =&gt; prediabetes + T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) Abnormalities increase AA&#39;s vs WA&#39;s =&gt; increased IR (lower Si or higher HOMA-IR) + hyperinsulinaemia + hepatic glucose overprodn or hepatic IR =&gt; healthy non-obese + mildly obese AA&#39;s vs WA&#39;s. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) Abnormalities come before development of prediabetes + T2D in AA&#39;s by decades. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Current study =&gt; modestly severely obese AA&#39;s =&gt; lower fasting + post glucose challenge serum glucose levels  vs WA&#39;s with prediabetes, BUT AA&#39;s have increased HbA1c levels vs WA&#39;s. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) Current study =&gt; mean fasting + post challenge levels + corresponding serum insulin + C-peptide levels =&gt; lower in modestly severely obese AA&#39;s vs WA&#39;s with prediabetes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) Previous study =&gt; mildly obese or overweight AA&#39;s =&gt; prediabetic subjects =&gt; prior poor B-cell function, (assessed by serum insulin + C-peptide levels). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Current study =&gt;  modestly severely obese AA&#39;s above point (L) =&gt; not the same. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Current study =&gt; serum insulin + C-peptide response =&gt; OGTT =&gt; corrected for prevailing glucose (insulinogenic index, insulin / glucose or C-peptide / glucose ratios) levels were similar in AA&#39;s + WA&#39;s with prediabetes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) Use of FSIVGTT =&gt; examines in detail =&gt; B cell function + insulin sensitivity in modestly severely obese AA&#39;s vs WA&#39;s with prediabtes. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) Modestly severely obese AA&#39;s with prediabetes =&gt; fairly well preserved B-cell function + ability to compensate =&gt; prevailing skeletal muscle IR vs WA&#39;s counterparts. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) Obesity =&gt; major cause of IR in general popn + T2D =&gt; no significant differences in Si values =&gt; modestly severe obese AA&#39;s + WA&#39;s with prediabetes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) Previous studies =&gt; in vivo total body glucose disposal consists =&gt; insulin mediated (Si) + non-insulin-mediated or glucose-mediated (Sg or GEZI) glucose disposal. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (W) Previous demonstrated =&gt; (Si) is lower + (Sg) is higher in healthy AA&#39;s with / without history of T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (X) Interesting that =&gt; higher Sg + GEZI values in obese AA&#39;s with prediabetes vs WA&#39;s. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Y) Our data =&gt; greater Sg + GEZI values =&gt; important compensatory mechns =&gt; maintain normal / nearly normal glucose tolerance =&gt; modestly severely obese AA&#39;s with prediabetes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Z) Mechn =&gt; putative  greater Sg + GEZI values =&gt; remains to be elucidated in obese + non-obese AA&#39;s with / without prediabetes. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (A1) Typical lipid + lipoprotein profiles =&gt; assoc. =&gt; obesity, T2D, IR + metabolic syndrome =&gt; higher serum TG + lower HDL-C levels. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B1) Insulin-resistant AA&#39;s =&gt; normal or higher HDL-C + apoA1 levels + lower serum TG levels vs WA&#39;s XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C1) Current study =&gt; modestly severely obese, IR, AA&#39;s with prediabetes =&gt; sig. lower serum TG levels, normal / higher HDL-C level + HDL / TG ratio + apoA1 level vs WA&#39;s with similar IR (Si). XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D1) Our Findings =&gt; favourable lipid + lipoprotein profiles in obese + non-obese AA&#39;s =&gt; independent of degree of obesity =&gt; lower serum TG levels + normal / higher HDL-C + apoA1 levels in AA&#39;s + other blacks of African ancestry. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E1) HDL =&gt; important anti-atherogenic lipoprotein =&gt; several critical roles in lipid transport + atherogenesis . Anti-atherogenic function of HDL =&gt; PON1 activity =&gt; cosegregation with HDL in the circulation. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F1) PON1 =&gt; Inhibits oxidn of LDL, suppresses inflammation , improves endothelial function + injury repair (anti-apoptotic effect) + increased reverse cholesterol transport activity. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G1) Recent findings =&gt; PON1 activity =&gt; 50% redn in non-diabetic post menopausal AA women vs WA&#39;s =&gt; unexpected. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H1) Our previously study =&gt; oxidised LDL + CRP levels =&gt; higher in non-diabetic, postmenopausal AA women vs WA&#39;s =&gt;  suggested that HDL was dysfunctional in AA&#39;s =&gt; play a critical role in atherogenesis in AA. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I1) Our study =&gt; did not examine =&gt; potential effects of the severity of obesity =&gt; cardiometabolic markers in AA&#39;s + WA&#39;s with prediabetes. XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J1) Present study =&gt; modestly severely obese + prediabetes =&gt; PON1 + oxidized LDL levels =&gt; not different in WA&#39;s + AA&#39;s =&gt; surprising + unexpected =&gt; further examined =&gt; qualitative functions of HDL =&gt; subclinical inflammation CRP + adipocytokines (IL-6). XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K1) Previous studies =&gt; increased CRP levels in obese AA&#39;s vs WA&#39;s XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L1) Current study =&gt; CRP + IL-6 levels =&gt; not statistically significant =&gt; modestly severely obese AA&#39;s with prediabetes vs WA&#39;s. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M1) Serum adiponectin =&gt; (very potent adipose derived insulin sensitizer) =&gt; redn rates of T2D, metabolic syndrome + CAD. XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N1) Serum adiponectin levels =&gt; redn in AA&#39;s + patients with obesity + IR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O1) Current study =&gt; adiponectin levels =&gt; lower BUT not significantly different =&gt; modestly severely obese AA&#39;s vs WA&#39;s with prediabetes. XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P1) Mechns =&gt; unknown =&gt; adaptive metabolic processes associated with severe degree of obesity =&gt; partly responsible. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q1) Several metabolic paradoxes in modestly severely obese AA&#39;s with prediabetes vs WA&#39;s. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R1) Modestly severely obese AA&#39;s + WA&#39;s with prediabetes =&gt; similar glucose responses + Si values =&gt; BUT req&#39;d diverse regulatory mechns. XXX X</td>
</tr>
<tr>
<td class="r data">23</td>
<td class="l data">Iron overload and diabetes risk: a shift from glucose to Fatty Acid oxidation and increased hepatic glucose production in a mouse model of hereditary hemochromatosis</td>
<td class="l data">(A) Increased tissue iron levels =&gt; associated with diabetes =&gt; human heretitory haemochromatosis (HH) + dietary iron overload. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) At least partially the result of decreased insulin secretion, tissue iron overload =&gt; significant changes in glucose metabolism in skeletal muscle. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) The effect on iron is to increase glucose uptake =&gt; a change that would be predicted to be protective of diabetes. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) To better understand the changes in overall fuel economy caused by iron =&gt; diabetes =&gt; investigated =&gt; muscle + hepatic =&gt; CHO + FA metabolism =&gt; mouse model =&gt; targeted deletion of the gene most commonly mutated in human HH, Hfe. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) Shown =&gt; Hfe -/- mice =&gt; shift in fuel preference from glucose =&gt; FA oxidn =&gt; in muscle. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) Decrease glucose oxidn in muscle =&gt; associated with =&gt; increased pyruvate / lactate recycling to liver =&gt; demonstrated by previous metabolic flux studies + increased hepatic glucose output (Cori cycling). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) These combined effects =&gt; increased prevalence of diabetes in individuals with HH. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) Our results =&gt; consistent with the close coupling of metabolism =&gt; iron availability =&gt; demonstrated in lower eukaryotes. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) Decreased glucose oxidn in skeletal muscle =&gt; partly due to decreased PDH activity. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Mechn =&gt; likely =&gt; observed increase in PdK4 mRNA, PDK4 activity =&gt; regulated at the transcription level. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) Candidate mediator for regulation of PdK4 =&gt; may be increased AMPK activity =&gt; previously reported =&gt; Hfe -/- mouse muscle. XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) Other factors contributing to decreased glucose oxidn =&gt; modest degree of mitochondrial dysfunction + increased FA oxidn. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Mitochondrial dysfunction in Hfe -/- muscle =&gt; relatively minor contributors =&gt; given the increased capacity for FA oxidn apparent in mice on high-fat diets. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Mechn =&gt; increased FA oxidn =&gt; increased AMPK activation + decreased ACC activity. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) Increase Cptb expression =&gt; may play a role + changes in malonyl-CoA (not assessed). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) Related to current findings =&gt; mice overexpressing erythropoietin in muscle =&gt; exhibit a similar phenotype to iron-overloaded mice =&gt; increased FA oxidn, decreased glucose oxidn + protection from diet-induced obesity (iron levels not measured in this model). XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) Iron sufficiency =&gt; facilitate unimpaired erthropoiesis =&gt; advantageous for iron-sufficient mouse to shift to the more energy-efficient BUT oxygen-inefficient fuel source of FA&#39;s to make use of that capacity for oxygen transport. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) Under opposite condition of hypoxia =&gt; FA oxidn decrease, enzymes for fat metabolism downregulate + glucose oxidn increases. X XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) The adaptive relationship between iron + fuel choice, Hfe -/- mice =&gt; consume more oxygen + produce more heat when fat is available in the diet. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) Decreased ability =&gt; transfer between utilization of CHO + lipid fuel sources =&gt; metabolic inflexibility =&gt; characteristic =&gt; metabolic syndrome + T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) Data, most consistent =&gt; increased hepatic glucose prodn =&gt; increased recycling of lactate + pyruvate (previously documented by isotopmer analysis of the fate of 1, 2 [13C] glucose. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (V) Increase in hepatic glucose prodn =&gt; mainly substrate driven =&gt; levels of mRNA for gluconeogenic enzymes =&gt; not increased + glucose prodn =&gt; exogenous pyruvate =&gt; not enhanced. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (W) Data =&gt; do not support changes in insulin signalling as the underlying cause of the phenotype. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (X) CONCLUSIONS =&gt; Diabetes risk engendered by iron operates not only through toxic effects on B cells mediated by increased oxidative stress + mitochondrial dysfunction. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Y) Liver of Hfe -/- mice exhibits increased glucose output with patterns of hepatic gene regulation + metabolite levels suggesting that gluconeogenesis in largely substrate-driven + results from altered fuel choice in muscle. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Z) Findings =&gt; help elucidate the association between iron + diabetes =&gt; not only in haemochromatosis BUT not-haemochromatotic individuals with metabolic syndrome or T2D associated with dietary iron excess. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (A1) Chronically increased fat oxidation, especially in the setting of decreased mitochondrial function, might also contribute to the accumulation of lipid products that have been implicated in the pathogenesis of diabetes (41). Whether these pathways contribute to increased diabetes risk in human hemochromatosis, however, is unknown. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B1) We previously demonstrated no change in basal or insulin-stimulated (in vivo) pAkt in skeletal muscle (18), and herein we shown that the increased hepatic glucose production occurs in the face of paradoxically increased insulin signaling in liver (Fig. 5D and E). Why insulin signaling is upregulated is not known. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C1) Levels of the insulin-sensitizing adipokine have been shown to be elevated in Hfe-/- mice (18), but other unknown factors may also contribute, including compensation for decreased insulin levels (17) or decreased inflammatory signaling in macrophages based on their lower iron content (42). Why this increased insulin signaling does not translate to decreased levels of gluconeogenic enzymes is unclear and is under investigation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">24</td>
<td class="l data">miR-375 enhances palmitate-induced lipoapoptosis in insulin-secreting NIT-1 cells by repressing myotrophin (V1) protein expression</td>
<td class="l data">(A) Previous studies =&gt; progressive deterioration in B-cell function + B-mass in T2D + redn of B-mass =&gt; accelerated apoptosis =&gt; increased FFA =&gt; pivotal predisposing factors responsible for B-cell apoptosis. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) Recent studies =&gt; importance for one particular islet specific miRNA, mir-375 =&gt; regulation of B-cell function + maintenance of normal pancreatic a- + B-mass. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) Present study =&gt; examined the role of mir-375 =&gt; regulation of palmitate-induced B-cell lipoapoptosis. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) NIT-1 cells =&gt; a NOD derived B-cell line, with ectopic mir-375 duplexes =&gt; much more susceptible to plamitate induced lipoapotosis. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) In contrast =&gt; NIT-1 cells =&gt; resistant to palmitate-induced lipoapoptosis once endogenous mir-375 =&gt; suppressed =&gt; specific antisense oligo, 2&#39;-o-Me-375. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) Expression levels of V1 protein =&gt; inversely assoc. =&gt; B-cell lipoapotosis. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) V1 =&gt; could be a target for mir-375 + mir-375 =&gt; increased B cell lipoapoptosis =&gt; redn V1 expressions in B cells. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) Cellular popn =&gt; particular organ =&gt; balance between rates of cell division + programmed cell death (apoptosis). XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) Once =&gt; increased apoptosis rate + redn cell replication =&gt; redn in cell popn occurs =&gt; organ decompensation. Loss of B-mass late in the course of obesity =&gt; typical example =&gt; B cell apoptosis exceeds cell division =&gt; predisposes development of T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Lipoapoptosis =&gt; type of apoptosis caused by dysregulated lipid metabolism =&gt; occurs in obesity + aging. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) Excessive accumulation =&gt; LCFA&#39;s =&gt; altered leptin liporegulation=&gt; non-adipose tissue e.g. pancreatic islets =&gt; exposed to an excess of LCFA&#39;s =&gt; cell would undergo lipoapoptosis. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) Effects of thermal, hypoxic or cytotoxic factors on apoptosis =&gt; well demonstrated vs metabolic causes of programmed cell death =&gt; lipoapoptosis =&gt; recieved less attention. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Recent studies =&gt; ZDF(fa/fa) rats =&gt; important role of ceramide pathway =&gt; late destructive phase =&gt; lipid overload =&gt; pancreatic B cells =&gt; underlying mechns leading to lipoapoptosis =&gt; poorly understood. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Current study =&gt; strong evidence =&gt; pivotal role of miRNA =&gt; regulation of B cell lipoapoptosis. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) Immense potential of miRNA&#39;s =&gt; controllers of gene networks =&gt; substantial evidence =&gt; small non-coding RNA molecules =&gt; central role =&gt; variety of physiological processess =&gt; tissue differentiation, cell proliferation + apoptosis, miRNA&#39;s =&gt; growing class =&gt; non-coding RNA&#39;s =&gt; regulation of gene expression =&gt; translational repression. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) Our data =&gt; mir-375 =&gt; indispensible role in normal glucose homeostasis, B mass turnover in newborns + adaptive B-cell expansion =&gt; response to increase insulin demand in IR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) Our data =&gt; mir-375 =&gt; proapoptotic factor =&gt; pathogenesis of B-cell lipoapoptosis. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) Studies =&gt; some evolutionarily conserved proteins =&gt; characterized by neuronal cells =&gt; present in the pancreatic B cells =&gt; V1 is such a protein =&gt; highly expressed in both neuronal + pancreatic B cells. V1 (myotrophin) -12-KD protein =&gt; 3D-alignment =&gt; resembles a truncated 1KBa without the signal response domain + PEST sequence. V1-validated as an anti-apoptotic factor in cardiac myocytes, neuronal cells + fibroblasts. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) Current study =&gt; expression levels =&gt; V1 in NIT-1 cells =&gt; inversely associated with palmitate-induced lipoapoptosis =&gt; V1 could also act as an anti-apoptotic function =&gt; maintaining B cell viability. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) Limited our study =&gt; report one of the pivotal targets of mir-375 =&gt; pancreatic islet-specific V1 protein =&gt; possible =&gt; mir-375 =&gt; targets additional factors =&gt; implicated in regulation of B-cell apoptosis. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) Recent study =&gt; mir-375 =&gt; could target PDK1 mRNA, a key molecule for PI3 kinase signalling in the pancreatic B cells =&gt; involved in the regulation of cell survival + proliferation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (V) Multiple signalling pathways =&gt; regulated by mir-375 by which mir-375 enhances B-cell lipoapoptosis. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (W) Modified synthetic anti-miRNA oligonucleotides (AMO&#39;s) =&gt; useful tools for specific repression of targeted miRNA expressions =&gt; unravel the function of miRNA&#39;s + their targets. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (X) 2&#39;-o-methyl oligonucleotides =&gt; irreversibly inhibit small RNA function in vitro + intact cells in a sequence specific fashion =&gt; stoichiometric binding to RISCs containing cognate miRNA =&gt; preventing interaction with its mRNA targets. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Y) Antisense-based oligonucleotides (ASOs), AMOs may contribute to the prioritzation of pharmaceutical targets =&gt; potential to progress into a new class of therapeutic agents. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Z) 2&#39;ome =&gt; modified anti-mir-375 oligonucleotide =&gt; high potency repression of endogenous mir-375 expressions =&gt; NIT-1 cells. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (A1) 2&#39;-o-me-375 transfected NIT-1 cells =&gt; almost completely protected from palmitate-induced lipoapoptosis, 2&#39;-o-Me-375 =&gt; useful &quot;off-target&quot; reagent =&gt; mir-375 =&gt; significant implications =&gt; experimental + clinical studies. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B1) Impaired B-cell function + possibly B-cell mass deficit =&gt; reversible =&gt; particularly at early stage of disease =&gt; limiting threshold for reversibility of the redn B-mass has probably. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C1) mir-375 =&gt; pancreatic islet-specific miRNA =&gt; pivotal regulator of lipoapoptosis =&gt; pancreatic B-cells. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D1) Although recent studies in ZDF (fa/fa) rats suggested an important role for the ceramide pathway in the late destructive phase of lipid overload in the pancreatic β cells [16], the overall underlying mechanisms leading to lipoapoptosis remained poorly understood. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (E1) Taking into account that mir-375 also regulates insulin secretion, mir-375 could emerge as a potential therapeutic target for prevention and intervention of β-cell dysfunction and β-mass loss in type 2 diabetes.</td>
</tr>
<tr>
<td class="r data">25</td>
<td class="l data">Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity</td>
<td class="l data">(A) Subtle aberrations in lipid metabolism occur in obesity + T2D =&gt; MS technology =&gt; detection of altered acyl-CN levels =&gt; detection of mild defects in FAO. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) Hypothesized =&gt; detect FAO defects =&gt; obese partipants +/- T2D. XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) Primary focus =&gt; skeletal muscle FAO, plasma acylCN =&gt; derived from other tissues =&gt; liver + cardiac muscle. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Increased acylCNs =&gt; serum + skeletal muscle from IR rats =&gt; no increase observed in liver =&gt; serum acylCN originated mainly from skeletal muscle. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) Obese + T2D subjects =&gt; increase NEFA&#39;s and similar BMI&#39;s equally accumulated acylCNs =&gt; full length FA&#39;s + 1st intermediates of B-oxidn. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) T2D subjects =&gt; accumulated a wide variety of later B-oxidn intermediates. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Esterification of FA&#39;s with glycerol-3 phosphate =&gt; TAG which is exported from the liver as VLDL to adipose tissue. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) When NEFA release was inhibited by short term insulin clamp =&gt; plasma acylCN values redn =&gt; significant blunted response in the T2D =&gt; would be expected if they are &quot;metabolically inflexible&quot;. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) Interpretations were based on acylCN profiles of patients with known genetic disorders of mitochondrial FAO. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) AcylCN profile includes substrates of both FA&#39;s + amino acid (AA) B oxidn. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Even chain acylCNs =&gt; containing up integrative physiology to 20 carbons accumulate in response to incomplete FA B-oxidn. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) In contrast =&gt; AA catabolism =&gt; odd-chain length species e.g. C3-CN BUT C4-CN derived from either AA or FA metabolism. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) Acetyl (C2)-CNs =&gt; derive from CHO metabolism =&gt; ultimate product of B-oxidn, acetyl-CoA. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Overnight fast =&gt; FAO is stimulated =&gt; increased saturated acylCN levels =&gt; BCAA metabolism is spared =&gt; redn C5 entry from leucine + isoleucine =&gt; redn C5-CN levels. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Obese + T2D =&gt; increased NEFA&#39;s during fasting =&gt; do they efficiently process this flood of FA&#39;s? XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) One locus of regulation =&gt; limitation of entry into B oxidn by CPT1 =&gt; trans-esterifies the activated long chain acyl-CoA to it&#39;s acylCN before entry into mitochondria. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) This regulation limits =&gt; C16-, C18- + C18:1-CN levels =&gt; increased free-CN: C16-CN. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) Obese / T2D =&gt; similarly C16-, C18-, and C18:1-CN + free-CN =&gt; free-CN:C16-CN ratio redn in obese participants (P&lt;0.05) similar trend in T2D (P&lt;0.07). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) Finding =&gt; inconsistent with CPT1-based limitation of B-oxidn flux =&gt; both obesity / T2D =&gt; similar quantities of NEFA&#39;s =&gt; readily activated into acylCN =&gt; mitochondria via carnitine acylCN translocase or exit the cell for other disposal. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) AcylCN is de-esterified back to acyl-CoA + enters the B-oxidn spiral (mitochondria). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) Increased levels of C14:1-CN + C16-OH-CN =&gt; species that are created from the initial rounds of B-oxidn =&gt; involving very-long-chain acyl-CoA dehydrogenase + long-chain 3-hydroxyacyl-CoA dehydrogenase, respectively =&gt; yielding unaltered C14:-CN:C16-CN + C16-OH-CN: CN : C16-CN ratios. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) Overall pattern =&gt; obese / T2D =&gt; similarly increase initial fluxes through B-oxidn in response to elevated NEFA&#39;s rather than having a CPT1 generated block =&gt; suggested previously. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (V) AcylCNs of =&lt; 10 carbon&#39;s =&gt; pattern of acylCN accumulation by groups diverged. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (W) Most straight-chain + hydroxy-acylCN products =&gt; later steps of B oxidn (medium + short chain processing) accumulated in a stepwise pattern =&gt; non-significant increase in the obese subjects =&gt; significant increase in T2D subjects =&gt; several species significantly increase in T2D vs obese + lean subjects. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (X) C8-CN:C16-CN ratio =&gt; significantly increase in T2D vs obese subjects =&gt; supporting trend =&gt; more severe defect in the T2D participants. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Y) Trends =&gt; consistent with a study of rat diabetic myocardium =&gt; overall acylCN levels increase accumulation of 3-OH-AcylCN&#39;s XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Z) T2D =&gt; second more global defect =&gt; mitochondrial dysfunction =&gt; enhanced accumulation of intermediates =&gt; chain-shortened -straight-chain products of FAO (C4- to C14-CN) =&gt; generalized dysfunction either FAO or at the interface of FAO + the (electron transport chain) ETC. XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (A1) Accumulation of intermediates from substrates that would be expected to decrease in quantity rather than accumulating during fasting =&gt; e.g. products of BCAA oxidn (C5-, C5-OH, C3-CN). XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B1) T2D + obese subjects =&gt; BMI, waist circumference (WC) + basal free fatty acid (FFA&#39;s) levels =&gt; almost identical =&gt; more &quot;abnormal&quot; acylCN patterns =&gt; not due to increased body fat or basal NEFA levels =&gt; likely result from IR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C1) Insulin infusion studies =&gt; further support hypothesis =&gt; T2D differ in their FAO regulation + response to insulin infusion =&gt; all acylCN species reduced significantly. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D1) Plasma acylCN species =&gt; responsive to start-term alterations in NEFA levels =&gt; however =&gt; T2D =&gt; blunted redn in the levels of many acylCNs =&gt; acylCN pattern =&gt; did not normalize to the extent observed in the obese group. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E1) Increase NEFA levels + redn RQ =&gt; T2D during insulin infusion =&gt; suggest =&gt; insulin clamp =&gt; did not block release of FFA&#39;s or flux into B-oxidn to the degree found in either lean or obese participants. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F1) Findings =&gt; consistent =&gt; hypothesis =&gt; T2D =&gt; metabolic inflexibility. X XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G1) Only one other group has reported redn plasma acylCN&#39;s (C10-, C12-, + C14:1-CN) + insulin =&gt; in response to OGTT.  XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H1) One marker of abnormal FAO =&gt; specially associated with T2D. C4DC-CN levels in T2D =&gt; nearly double than those observed in obese or lean participants. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I1) C4DC-CN correlated highly with fasting plasma glucose (r=0.72) + with HbA1c (r=0.74) =&gt; AcylCN species =&gt; biomarker =&gt; intersection of combined gluco + lipotoxicity. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J1) C4DC-CN =&gt; identified =&gt; methodology =&gt; sum of both methyl-malonyl-carnitine + succinyl-carnitine =&gt; same molecular mass. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K1) Additional analyses =&gt; req&#39;d =&gt; specifically identify affected species. X XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L1) Whether th</td>
</tr>
<tr>
<td class="r data">26</td>
<td class="l data">Insulin resistance and body fat distribution in South Asian men compared to Caucasian men</td>
<td class="l data">(A) This study =&gt; compared characteristics of body fat content + distribution between South Asian (SA) + Caucasian (CA) men with similar BMI, + functional characteristic of adipose tissue, esp. related to insulin sensitivity (IS). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) BMI, WAIST CIRCUMFERENCES (WC) and % TOTAL BODY FAT =&gt; for a given BMI or WC =&gt; SA men had 6% higher total body fat then CA men. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) Findings =&gt; threshold for obesity in SA&#39;s approx. 2kg/m2 lower vs CA&#39;s. A WC of 10cm lower in SA&#39;s confers a similar estimate of % body fat. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Discrepancies =&gt; indicative of body fat content =&gt; adjustments required for BMI or WC to define obesity =&gt; did not entirely account for possible differences in inherent IR in the SA popn. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) ETHNIC DIFFERENCES IN VISCERAL FAT =&gt; did not find that SA&#39;s preferentially deposit fat in visceral adipose tissue, despite SA&#39;s having higher % body fat, =&gt; did not have a higher absolute amount or % of total fat as visceral fat. Particularly evident =&gt; two groups were matched for % body fat. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) Ratio&#39;s of intraperitoneal fat / abdominal subcutaneous fat higher in CA men vs SA&#39;s. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) Ratio&#39;s observed in CA&#39;s are similar to those reported for a large popn of CA men =&gt; Dallas Heart Study. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (H) Lower ratio&#39;s =&gt; not prone to preferential deposition of body fat in the visceral compartment =&gt; unlikely =&gt; increased IR found in SA&#39;s =&gt; explained by preferential accumulation of visceral fat. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) TRUNCAL SKINFOLDS AND HIP CIRCUMFERENCE =&gt; In spite of higher % body fat for a given BMI in SA&#39;s  =&gt; no differences in hip circumferences between the two groups, or in waist-to-hip ratios. XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Truncal skinfolds thicknesses increase in SA&#39;s =&gt; implies that SA&#39;s =&gt; preferential accumulation in truncal fat vs gluteofemoral fat. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) If SA&#39;s have preference for body fat compartmentalization =&gt; it is for truncal subcutaneous fat + not visceral fat =&gt; finding consistent with previous reports =&gt; shown strong relationship between subcutneous fat + IR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) Shown for the 1st time =&gt; truncal skinfolds =&gt; predict % total body fat independent of ethnicity. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) ADIPOCYTE SIZE =&gt; potentially important finding =&gt; in this study =&gt; SA&#39;s had larger abdominal subcutaneous adipocytes vs CA&#39;s =&gt; this is true =&gt; when the two groups were compared at similar body fat contents. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Growing body of evidence =&gt; large adipocytes are dysfunctional =&gt; they predict IR + T2D independent of obesity. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) Enlarged subcutaneous abdominal adipocyte size, BUT not obesity itself =&gt; predicts T2D independent of IR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) Genetic factors influencing adipocytes size =&gt; play a role in IR. Even if a predisposition to IR observed in SA&#39;s =&gt; cannot be attributed to preferential accumulation of visceral fat. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) The question can still be asked  =&gt; whether all the excess IR observed in SA popn =&gt; can be explained =&gt; hidden high body-fat content =&gt; or perhaps =&gt; excess of truncal subcutaneous fat. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) Shown previously =&gt; increased body fat content =&gt; progressively lower insulin-mediated glucose disposal rates =&gt; likely that increased IR observed in SA&#39;s =&gt; explained by &quot;hidden&quot; obesity =&gt; excess body fat content NOT seen with standard BMI or WC measurements + increased possibility =&gt; predisposition for deposition of fat in the trunk accentuates IR. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) Previous studies =&gt; truncal fat =&gt; metabolically more active vs lower body fat =&gt; if so =&gt; maldistribution of body fat in SA&#39;s =&gt; contributes significantly =&gt; increase IR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) This study =&gt; evidence that supports =&gt; preferential accumulation of truncal fat in SA&#39;s =&gt; + metabolic profile =&gt; predisposes to IR + T2D. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) Large adipocytes =&gt; consistent with previous studies =&gt; &quot;dysfunctional&quot; characteristics of large cells. Our study =&gt; abdominal adipose size =&gt; inversely correlated =&gt; glucose disposal rates + adiponectin levels. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (V) Subgroups were matched for % body fat, adipocytes size =&gt; still significantly greater in SA&#39;s + glucose disposal rates + adiponectin levels reduced + leptin levels increase in SA&#39;s =&gt; confirming previous reports. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (W) Current study =&gt; insights =&gt; for a given BMI, WC or waist-to-hip ratio =&gt; increase % total body fat is CA&#39;s. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (X) Preferentially accumulate body fat in truncal (+ abdominal) subcutaneous adipose tissue =&gt; NOT in visceral adipose tissue =&gt; this maldistribution of body fat =&gt; metabolic abnormalities beyond total body fat. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Y) SA =&gt; increased adipocytes, increased NEFFA + redn adiponectin =&gt; dysfunctional adipose tissue =&gt; role in metabolic abnormalities beyond total + truncal fat. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Z) SA men vs CA men =&gt; increase % total fat for a given BMI + preferentially accumulate this fat in truncal adipose tissue. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (A1) There is no accumulation of intraperitoneal fat, truncal adipose tissue in SA&#39;s =&gt; abnormally large adipocytes =&gt; likely are dysfunctional =&gt; as shown by high levels of NEFA + low levels of adiponectin. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B1) Abnormalities in adipose tissue =&gt; contribute importantly to increase IR observed in SA&#39;s. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C1) The major limitation of this study is the number of subjects investigated. The number was limited by the complexities of the metabolic and imaging studies. For this reason, addition studies are needed to confirm our conclusions. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
</tbody>
</table>
</div>
</div>
<br>
</div>
</body>
</html>
